Botulinum Toxin Formulation

Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects. 1. A pharmaceutical composition comprising a botulinum neurotoxin and a viscous carrier for the botulinum neurotoxin.2. The pharmaceutical composition of claim 1 , wherein the viscous carrier is selected from the group of viscous carriers consisting of hyaluronic acid claim 1 , carbomer claim 1 , polyacrylic acid claim 1 , cellulose polycarbophil claim 1 , polyvinylpyrrolidone claim 1 , gelatin claim 1 , dextrin claim 1 , polysaccharide claim 1 , polyacrylamide claim 1 , polyvinyl alcohol claim 1 , polyvinyl acetate claim 1 , chitosans claim 1 , algenates and derivatives and mixtures thereof.3. The pharmaceutical composition of wherein the viscous carrier is a hyaluronic acid.4. The pharmaceutical composition of wherein the viscous carrier is a hyaluronic acid is a non-cross linked hyaluronic acid.5. The pharmaceutical composition of wherein the hyaluronic acid is a cross linked hyaluronic acid.6. The pharmaceutical composition of wherein the hyaluronic acid is polymeric hyaluronic acid with a molecular weight between 10 claim 3 ,000 Daltons and 20 million Daltons.7. The pharmaceutical composition of wherein the concentration of hyaluronic acid in the pharmaceutical composition is between 1 wt % and 10 wt %.8. The pharmaceutical composition of wherein the concentration of hyaluronic acid in the pharmaceutical composition is between 0.1 wt % and 1 wt %.9. The pharmaceutical composition of wherein the viscosity of the pharmaceutical composition is between 1000 cps and 300 claim 4 ,000 cps at 25° C. claim 4 , at a shear rate of 0.1/second.10. The pharmaceutical composition of wherein the viscosity of the pharmaceutical composition is between 100 cps and 1 claim 5 ,000 cps at 25° C. claim 5 , at a shear rate of 0.1/second.11. A pharmaceutical composition comprising a ...

NON-PROTEIN STABILIZED CLOSTRIDIAL TOXIN PHARMACEUTICAL COMPOSITIONS

A Clostridial toxin pharmaceutical composition comprising a Clostridial toxin, such as a botulinum toxin, wherein the Clostridial toxin present in the pharmaceutical composition is stabilized by a non-protein excipient such as a polyvinylpyrrolidone, a disaccharides, a trisaccharide, a polysaccharide, an alcohol, a metal, an amino acid, a surfactant and/or a polyethylene glycol. 1. A pharmaceutical composition comprising:(a) a botulinum toxin, wherein the botulinum toxin is not stabilized by a protein excipient,(b) a polyvinylpyrrolidone, and;(c) a disaccharide,wherein the potency of the botulinum toxin is at least about 40% of the theoretical maximum potency of the botulinum toxin.2. The pharmaceutical composition of claim 1 , wherein the botulinum toxin is selected from the group consisting of the botulinum toxins types A claim 1 , B claim 1 , C claim 1 , D claim 1 , E claim 1 , F and G.3. The pharmaceutical composition of claim 1 , wherein the botulinum toxin is a botulinum toxin type A.4. A pharmaceutical composition comprising:(a) a botulinum toxin, wherein the botulinum toxin is not stabilized by a protein excipient,(b) a polyvinylpyrrolidone, and;(c) a disaccharide,wherein the potency of the botulinum toxin is at least about 50% of the theoretical maximum potency of the botulinum toxin.5. The pharmaceutical composition of claim 4 , wherein the botulinum toxin is selected from the group consisting of the botulinum toxins types A claim 4 , B claim 4 , C claim 4 , D claim 4 , E claim 4 , F and G.6. The pharmaceutical composition of claim 4 , wherein the botulinum toxin is a botulinum toxin type A.7. A pharmaceutical composition comprising:(a) a botulinum toxin, wherein the botulinum toxin is not stabilized by a protein excipient,(b) a polyvinylpyrrolidone, and;(c) a disaccharide,wherein the potency of the botulinum toxin is at least about 60% of the theoretical maximum potency of the botulinum toxin.8. The pharmaceutical composition of claim 7 , wherein the ...

Inhibiting Aberrant Blood Vessel Formation Using Growth Factor Retargeted Endopeptidases

The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal using such TVEMP compositions. 1. A method of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal , the method comprising the step of administering to the mammal in need thereof a therapeutically effective amount of a composition including a TVEMP comprising a targeting domain , a Clostridial toxin translocation domain and a Clostridial toxin enzymatic domain , and an exogenous protease cleavage site , wherein administration of the composition decreases a symptom of a disease or disorder associated with aberrant new blood vessel formation.2. The method of claim 1 , wherein the TVEMP comprises a linear amino-to-carboxyl single polypeptide order of 1) the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin translocation domain claim 1 , the targeting domain claim 1 , 2) the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the targeting domain claim 1 , the Clostridial toxin translocation domain claim 1 , 3) the targeting domain claim 1 , the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site and the Clostridial toxin enzymatic domain claim 1 , 4) the targeting domain claim 1 , the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin translocation domain claim 1 , 5) the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin enzymatic domain and the targeting domain claim 1 , or 6) the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site claim 1 , the targeting domain and the Clostridial toxin enzymatic domain.3. The method of claim 1 , wherein the ...

Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases

The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer or a disease of hyperproliferation in a mammal using such TVEMP compositions. 1. A method of treating benign prostatic hyperplasia in a mammal , the method comprising the step of administering to the mammal in need thereof a therapeutically effective amount of a composition including a TVEMP comprising a targeting domain , a Clostridial toxin translocation domain and a Clostridial toxin enzymatic domain , and an exogenous protease cleavage site , wherein the targeting domain is an arginine vasopressin targeting domain , a chemokine targeting domain , an interleukin targeting domain , a gonadotropin-releasing hormone targeting domain , or a Synovial Sarcoma X breakpoint targeting domain , and wherein administration of the composition reduces a symptom associated with benign prostatic hyperplasia.2. The method of claim 1 , wherein the TVEMP comprises a linear amino-to-carboxyl single polypeptide order of 1) the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin translocation domain claim 1 , the targeting domain claim 1 , 2) the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the targeting domain claim 1 , the Clostridial toxin translocation domain claim 1 , 3) the targeting domain claim 1 , the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site and the Clostridial toxin enzymatic domain claim 1 , 4) the targeting domain claim 1 , the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin translocation domain claim 1 , 5) the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin enzymatic domain and the targeting domain claim 1 , or 6) the Clostridial toxin translocation domain claim 1 , the ...

Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases

The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal using such TVEMP compositions. 1. A method of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal , the method comprising the step of administering to the mammal in need thereof a therapeutically effective amount of a composition including a TVEMP comprising an opioid targeting domain , a Clostridial toxin translocation domain and a Clostridial toxin enzymatic domain , and an exogenous protease cleavage site , wherein administration of the composition decreases a symptom of a disease or disorder associated with aberrant new blood vessel formation.2. The method of claim 1 , wherein the TVEMP comprises a linear amino-to-carboxyl single polypeptide order of 1) the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin translocation domain claim 1 , the targeting domain claim 1 , 2) the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the targeting domain claim 1 , the Clostridial toxin translocation domain claim 1 , 3) the targeting domain claim 1 , the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site and the Clostridial toxin enzymatic domain claim 1 , 4) the targeting domain claim 1 , the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin translocation domain claim 1 , 5) the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin enzymatic domain and the targeting domain claim 1 , or 6) the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site claim 1 , the targeting domain and the Clostridial toxin enzymatic domain.3. The method of claim 1 , ...

Treatments Using PSMA Ligand Endopeptidases

The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a prostate cancer, a benign prostatic hyperplasia, and/or neovascularization or pathological angiogenesis associated with a cancer in a mammal using such TVEMP compositions. 1. A method of treating a prostate cancer in a mammal , the method comprising the step of administering to the mammal in need thereof a therapeutically effective amount of a composition including a TVEMP comprising a Prostate-Specific Membrane Antigen targeting domain , a Clostridial toxin translocation domain and a Clostridial toxin enzymatic domain , and an exogenous protease cleavage site , wherein administration of the composition reduces a symptom associated with the prostate cancer.2. The method of claim 1 , wherein the TVEMP comprises a linear amino-to-carboxyl single polypeptide order of 1) the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin translocation domain claim 1 , the targeting domain claim 1 , 2) the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the targeting domain claim 1 , the Clostridial toxin translocation domain claim 1 , 3) the targeting domain claim 1 , the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site and the Clostridial toxin enzymatic domain claim 1 , 4) the targeting domain claim 1 , the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin translocation domain claim 1 , 5) the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin enzymatic domain and the targeting domain claim 1 , or 6) the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site claim 1 , the targeting domain and the Clostridial toxin enzymatic domain.3. The method of claim 1 , wherein the ...

Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases

The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal using such TVEMP compositions. 1. A method of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal , the method comprising the step of administering to the mammal in need thereof a therapeutically effective amount of a composition including a TVEMP comprising a targeting domain , a Clostridial toxin translocation domain and a Clostridial toxin enzymatic domain , and an exogenous protease cleavage site , wherein administration of the composition decreases a symptom of a disease or disorder associated with aberrant new blood vessel formation.2. The method of claim 1 , wherein the TVEMP comprises a linear amino-to-carboxyl single polypeptide order of 1) the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin translocation domain claim 1 , the targeting domain claim 1 , 2) the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the targeting domain claim 1 , the Clostridial toxin translocation domain claim 1 , 3) the targeting domain claim 1 , the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site and the Clostridial toxin enzymatic domain claim 1 , 4) the targeting domain claim 1 , the Clostridial toxin enzymatic domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin translocation domain claim 1 , 5) the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site claim 1 , the Clostridial toxin enzymatic domain and the targeting domain claim 1 , or 6) the Clostridial toxin translocation domain claim 1 , the exogenous protease cleavage site claim 1 , the targeting domain and the Clostridial toxin enzymatic domain.3. The method of claim 1 , wherein the ...

Animal Protein-Free Pharmaceutical Compositions

Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients. 1. An animal-protein free , solid-form Clostridial toxin pharmaceutical composition comprising a Clostridial toxin active ingredient , an effective amount of lactose , an effective amount of sucrose , and an effective amount of sodium chloride; andwherein after storage for one year the pharmaceutical composition exhibits a recovered potency of the Clostridial toxin active ingredient of at least 20% when reconstituted into a form suitable for injection.2. The composition according to claim 1 , wherein the storage temperature is below freezing.3. The composition according to claim 1 , wherein the storage temperature is at ambient temperatures.4. The composition according to claim 1 , wherein the storage temperature is below freezing and the recovered potency is at least 40%.5. The composition according to claim 1 , wherein the storage temperature is at ambient temperatures and the recovered potency is at least 40%. This application is a continuation of U.S. patent application Ser. No. 12/331,816 filed Dec. 10, 2008, which is a continuation-in-part that claims priority pursuant to 35 U.S.C. §120 to U.S. patent application Ser. No. 11/524,683, filed on Sep. 21, 2006, a patent application which claims priority pursuant to 35 U.S.C. §119(e) to U.S. Provisional Application No. 60/725,126, filed Oct. 6, 2005, each of which is hereby incorporated by reference in its entirety.A pharmaceutical composition is a formulation comprises at least one active ingredient and at least one inert ingredient, called an excipient, used as a diluent or vehicle for the active ingredient. An excipient is useful in one or more of the following as a stabilizing agent, a bulking agent, a cryo-protectant, a lyo-protectant, a preservative, and a buffer. A pharmaceutical composition can be processed into a solid form, such as, e.g., a lyophilized ...

RETAINER ASSEMBLY FOR SWIVEL SPOUT

A swing spout assembly is disclosed which has a spout having a channel extending from an inlet end to a discharge end. A radially extending groove is formed adjacent the inlet end of the spout, and a snap ring is received in the groove of the spout. A pair of glides in the form of wear washers sandwich the portion of the snap ring extending out of the groove to form a bearing subassembly. An escutcheon is positioned around at least part of the inlet end of the spout. A stationary body has a portion that extends into the channel of the spout and a portion extending around an outer radial periphery of the inlet end of the spout. The portion extending around the outer periphery of the inlet end and the escutcheon defining a pocket that retains the bearing sub-assembly. 1. A swing spout assembly , comprising;a spout having a channel extending from an inlet end to a discharge end, the inlet end having a groove formed therein;a snap ring configured to engage the groove of the inlet end;an escutcheon disposed around the inlet end of the spout; anda stationary body having a portion configured to extend into the channel of the spout;wherein the spout is configured to swivel relative to the escutcheon and the stationary body.2. The swing spout assembly of claim 1 , wherein the stationary body further comprises a second portion configured to extend around the inlet end of the spout and the snap ring to help define a pocket that retains the snap ring.3. The swing spout assembly of claim 2 , wherein the escutcheon includes a recess that is configured to receive the second portion of the stationary body.4. The swing spout assembly of claim 2 , further comprising a washer disposed between the snap ring and the second portion of the stationary body.5. The swing spout assembly of claim 1 , further comprising a washer disposed between the snap ring and the escutcheon.6. The swing spout assembly of claim 1 , wherein the escutcheon includes a groove in a surface disposed adjacent to ...

PHARMACEUTICAL COMPOSITIONS CONTAINING BOTULINUM NEUROTOXIN

This invention relates to the use of a composition comprising a polysaccharide and a toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D. 1botulinum. A pharmaceutical composition comprising a collagen and a toxin.2botulinum. The pharmaceutical composition of claim 1 , wherein the botulinum toxin is selected from the group consisting of toxin types A claim 1 , B claim 1 , C claim 1 , D claim 1 , E claim 1 , F and G.3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition has a pH of between about 5 and 7.3 when reconstituted or upon injection.4botulinum. The pharmaceutical composition of claim 1 , wherein the botulinum toxin comprises a toxin complex.5botulinum. The pharmaceutical composition of claim 4 , wherein the botulinum toxin complex comprises a toxin complex type A.6botulinum. The pharmaceutical composition of claim 4 , wherein the botulinum toxin complex comprises a toxin complex type B This application is a divisional of application Ser. No. 11/539,778, filed Oct. 9, 2006, which is a divisional of application Ser. No. 11/303,000, filed Dec. 13, 2005, which is a continuation of application Ser. No. 10/359,828, filed Feb. 7, 2003, which is a continuation in part of application Ser. No. 10/288,738, filed Nov. 5, 2002, which is a continuation in part of application Ser. No. 10/047,058, filed Jan. 14, 2002, which is a continuation in part of application Ser. No. 09/500,147, filed Feb. 8, 2000 (now abandoned). The entire contents of these prior patent applications are incorporated herein by reference.This invention relates to pharmaceutical compositions comprising a polysaccharide and a toxin, and uses thereof, such as to treat a facial wrinkleThe present invention relates to toxin pharmaceutical compositions. In particular, the present invention relates ...

BOTULINUM TOXIN COMPOSITIONS

A high potency botulinum toxin pharmaceutical composition comprising two excipients (such as albumin and sodium chloride) in a weight to weight ratio of between about 1 and about 100. 1. A lyophilized pharmaceutical composition comprising:{'sup': −11', '−11, '(a) between about 2.0×10grams and about 3.5×10grams of a botulinum toxin type A for each unit of botulinum toxin present in the pharmaceutical composition, the unit of the botulinum toxin being determined by a mouse LD50 potency assay;'}(b) an albumin, and(c) a polysorbate,(d) wherein the composition components are mixed and lyophilized, and the weight to weight ratio of the albumin to the polysorbate present in the pharmaceutical composition is greater than 0.6 and less than about 100.2. The pharmaceutical composition of claim 1 , wherein the botulinum toxin is present as a botulinum toxin complex.3. The pharmaceutical composition of claim 1 , wherein the botulinum toxin is present as a pure botulinum toxin.4. The pharmaceutical composition of claim 1 , wherein the albumin is a serum albumin.5. The pharmaceutical composition of claim 1 , wherein the albumin is a recombinant albumin.6. The pharmaceutical composition of claim 5 , wherein the botulinum toxin is present as a botulinum toxin complex.7. The pharmaceutical composition of wherein the botulinum toxin is present as a pure botulinum toxin.8. A lyophilized pharmaceutical composition claim 5 , comprising:(a) a botulinum toxin;(b) a polysorbate, and;(c) an albumin;wherein the composition components are mixed and lyophilized, and the potency of the botulinum toxin present in the pharmaceutical composition is between about 24 units/ng and about 60 units/ng, and further wherein the weight to weight ratio of the albumin to the polysorbate is greater than 0.6 and less than about 100.9. The pharmaceutical composition of claim 8 , wherein the albumin is a serum albumin.10. The pharmaceutical composition of claim 8 , wherein the albumin is a recombinant albumin. ...

Renal nerve denervation via the renal pelvis

Apparatus, systems, and methods provide access to the renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances.

Methods of Treating Cancer Using Growth Factor Retargeted Endopeptidases

The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions. 1. A method of treating cancer in a mammal, the method comprising the step of administering to the mammal in need thereof a therapeutically effective amount of a composition including a TVEMP comprising a targeting domain, a Clostridial toxin translocation domain and a Clostridial toxin enzymatic domain, and an exogenous protease cleavage site, wherein administration of the composition reduces a symptom associated with cancer. This patent application claims priority pursuant to 35 U.S.C. §119(e) to U.S. Provisional Patent Application Ser. No. 61/233,947 filed Aug. 14, 2009, which is hereby incorporated by reference in its entirety.Cancer is a group of more than 100 diseases in which a group of cells display uncontrolled growth (cell division beyond the normal limits). In most cases, cancer cells form a clump of cells called a tumor, although in some cancers, like leukemia, the cells do not form tumors. Tumors may be malignant or benign. Besides, malignant tumors (or cancers) comprise cells with abnormal genetic material and usually undergo rapid uncontrolled cell growth, invade and destroy adjacent tissue, and sometimes spread to other locations in the body via lymph or blood (i.e., metastasis). Cancer is associated with a high incidence of mortality because if the invasion and metastasis of the cancer cells throughout the body are not stopped, cancer cells will invade vital organs and lead to the dysfunction of the organs and eventual death. The malignant properties of cancers differentiate them from benign tumors, which are usually slow-growing and self-limited, do not invade or metastasize, and as such, are generally not life-threatening. Cancers at the local, regional or distant stage are considered invasive. A very early cancer found in only a few layers of cells, called in situ cancer, is considered non- ...

ASYMMETRIC SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOSULFONE COMPOUNDS

Processes for synthesizing aminosulfone compounds are provided. Aminosulfone compounds obtained using methods provided herein are useful in production or synthesis of sulfone group containing isoindoline based compounds. 2. The process of claim 1 , wherein Rand Rare substituted or unsubstituted (C-C)alkoxy claim 1 , or an isotopologue thereof.3. The process of claim 2 , wherein Ris OMe claim 2 , or an isotopologue thereof claim 2 , Ris OEt claim 2 , or an isotopologue thereof claim 2 , and Ris Me claim 2 , or an isotopologue thereof.4. The process of claim 1 , wherein the metal catalyst contains rhodium.5. The process of claim 4 , wherein the metal catalyst is Rh(cod)OTf.6. The process of claim 1 , wherein the chiral ligand or chiral metal catalyst/ligand complex is (S claim 1 ,R)-t-Bu Josiphos claim 1 , Josiphos SL-J011-2 claim 1 , (S claim 1 ,S)-Me-Duphos claim 1 , (S claim 1 ,S)-Chiraphos claim 1 , (R)-Phanephos claim 1 , (R)—Ru(OAc)(DM-segphos) claim 1 , [(R claim 1 ,R)-Me-BPE]Rh(cod)BF claim 1 , (R)—C-TunePhos claim 1 , (R)—[Rh(cod)TCFP]BF claim 1 , or a stereoisomer thereof.7. The process of claim 6 , wherein the chiral ligand is (S claim 6 ,R)-t-Bu Josiphos.8. The process of claim 1 , wherein the load of catalyst is between about 0.05 mol % and about 5 mol %.9. The process of claim 1 , wherein the molar ratio of the chiral ligand to the metal catalyst is from about 3:1 to about 1:1.10. The process of claim 1 , wherein the hydrogen pressure is between about 15 psig and about 250 psig.11. The process of claim 1 , wherein the solvent is ethyl acetate claim 1 , diethyl ether claim 1 , tetrahydrofuran claim 1 , 1 claim 1 ,4-dioxane claim 1 , acetonitrile claim 1 , dichloromethane claim 1 , chloroform claim 1 , N-methylpyrrolidinone claim 1 , dimethyl formamide claim 1 , dimethyl sulfoxide claim 1 , formic acid claim 1 , acetic acid claim 1 , methanol claim 1 , ethanol claim 1 , isopropanol claim 1 , 2 claim 1 ,2 claim 1 ,2-trifluoroethanol claim 1 , or mixtures ...

Methods of Treating Cancer Using Glucagon-Like Hormone Retargeted Endopepidases

The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions. 1. A method of treating cancer in a mammal, the method comprising the step of administering to the mammal in need thereof a therapeutically effective amount of a composition including a TVEMP comprising a targeting domain, a Clostridial toxin translocation domain and a Clostridial toxin enzymatic domain, and an exogenous protease cleavage site, wherein administration of the composition reduces a symptom associated with cancer. This patent application is a continuation of U.S. application Ser. No. 12/856,936, filed Aug. 16, 2010, which claims priority to U.S. Provisional Patent Application Ser. No. 61/233,978 filed Aug. 14, 2009, which is hereby incorporated by reference in its entirety.Cancer is a group of more than 100 diseases in which a group of cells display uncontrolled growth (cell division beyond the normal limits). In most cases, cancer cells form a clump of cells called a tumor, although in some cancers, like leukemia, the cells do not form tumors. Tumors may be malignant or benign. Besides, malignant tumors (or cancers) comprise cells with abnormal genetic material and usually undergo rapid uncontrolled cell growth, invade and destroy adjacent tissue, and sometimes spread to other locations in the body via lymph or blood (i.e., metastasis). Cancer is associated with a high incidence of mortality because if the invasion and metastasis of the cancer cells throughout the body are not stopped, cancer cells will invade vital organs and lead to the dysfunction of the organs and eventual death. The malignant properties of cancers differentiate them from benign tumors, which are usually slow-growing and self-limited, do not invade or metastasize, and as such, are generally not life-threatening. Cancers at the local, regional or distant stage are considered invasive. A very early cancer found in only a few layers ...

PHARMACEUTICAL COMPOSITIONS CONTAINING BOTULINUM NEUROTOXIN

This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D. 1. A device comprising at least two chambers , wherein a first chamber comprises an acidic solution of Botulinum toxin , and a second chamber comprises a buffering solution , wherein the buffering solution is present in an amount sufficient to raise the pH of the acidic botulinum toxin solution to at or near physiological pH after mixing.2. The device of claim 1 , wherein the pH of said acidic solution of Botulinum toxin is about 3.0 to about 6.3. The device of claim 1 , wherein said acidic solution of Botulinum toxin comprises any combination of one or all of immunotypes A-G.4. The device of claim 1 , wherein said acidic solution of Botulinum toxin comprises about 1 to about 2000 LDunits of Botulinum toxin.5. A method of preparing a pharmaceutical formulation of Botulinum toxin comprising combining an acidic solution of Botulinum toxin and a buffering solution in a device of claim 1 , wherein the pH of said botulinum toxin formulation after mixing is at or near physiological pH. This application is a continuation of U.S. application Ser. No. 13/467,795, filed May 9, 2012, which is a divisional of application Ser. No. 11/539,778, filed Oct. 9, 2006, now U.S. Pat. No. 8,216,591, which is a divisional of application Ser. No. 11/303,000, filed Dec. 13, 2005, now U.S. Pat. No. 7,758,873, which is a continuation of application Ser. No. 10/359,828, filed Feb. 7, 2003, now U.S. Pat. No. 7,780,967, which is a continuation in part of is application Ser. No. 10/288,738, filed Nov. 5, 2002 (now abandoned), which is a continuation in part of application Ser. No. 10/047,058, filed Jan. 14, 2002 (now abandoned), which is a continuation in part of ...

Solvent-free oil dispersant

The present invention is directed toward an oil dispersant composition useful in treating oil spills, and for cleanup of the shoreline, animals, plants, and equipment. The oil dispersant product is a non-toxic, solvent-free composition which efficiently breaks down grease, grime and crude oil at the molecular level, by breaking down the hydrocarbon chains and preventing the oil molecules from ever reforming again.

Botulinum toxin compositions

A high potency botulinum toxin pharmaceutical composition comprising two excipients (such as albumin and sodium chloride) in a weight to weight ratio of between about 1 and about 100.

PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF

Processes for the preparation of certain isoindole compounds, and isotopologues thereof, are provided. In some embodiments, the processes comprise catalytic assymetrical hydrogenation with hydrogen gas or deuterium gas in a solvent containing exchangeable proton or deuterium for proton-deuterium exchange. 4. The process of claim 1 , wherein Yis hydrogen or deuterium; and Yand Yare both hydrogen or both deuterium.5. The process of claim 4 , wherein Yis hydrogen or deuterium; and Yand Yare both hydrogen or both deuterium claim 4 , wherein not all of Y claim 4 , Y claim 4 , and Yare hydrogen.7. The process of claim 1 , wherein Rand Rare substituted or unsubstituted (C-C)alkoxy claim 1 , or an isotopologue thereof.8. The process of claim 7 , wherein Ris OMe enriched with 0 claim 7 , 1 claim 7 , 2 claim 7 , or 3 deuterium claim 7 , and Ris OEt enriched with 0 claim 7 , 1 claim 7 , 2 claim 7 , 3 claim 7 , 4 claim 7 , or 5 deuterium.9. The process of claim 8 , wherein Ris OCD claim 8 , and Ris OEt.10. The process of claim 8 , wherein Ris OCD claim 8 , and Ris OCDCD.11. The process of claim 1 , wherein Ris Me enriched with 0 claim 1 , 1 claim 1 , 2 claim 1 , or 3 deuterium.14. The process of claim 1 , wherein R is methyl enriched with 0 claim 1 , 1 claim 1 , 2 claim 1 , or 3 deuterium or cyclopropyl enriched with 0 claim 1 , 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 claim 1 , or 5 deuterium.15. The process of claim 1 , wherein the hydrogenation in step (a) occurs with hydrogen gas.16. The process of claim 1 , wherein the hydrogenation in step (a) occurs with deuterium gas.17. The process of claim 1 , wherein the hydrogenation in step (a) occurs in a solvent containing exchangeable proton for proton-deuterium exchange.18. The process of claim 17 , wherein the solvent containing exchangeable proton for proton-deuterium exchange is 2 claim 17 ,2 claim 17 ,2-trifluoroethanol.19. The process of claim 1 , wherein the hydrogenation in step (a) occurs in a solvent containing ...

ANIMAL PROTEIN-FREE PHARMACEUTICAL COMPOSITIONS

Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients. 1. A method to stabilize a Clostridial neurotoxin , comprising:providing an aqueous solution comprising a Clostridial neurotoxin and a non-mammalian protein excipient; andcompounding the solution with one or more additional non-protein excipients to provide a formulation comprising the neurotoxin in stable form.2. The method of claim 1 , wherein compounding comprises adding the one or more additional non-protein excipients to water to form a solution and adding the aqueous solution thereto.3. A powder pharmaceutical composition claim 1 , comprising:a botulinum toxin, wherein the botulinum toxin is a type A serotype;a surfactant;at least one disaccharide selected from the group consisting of sucrose and trehalose; anda buffer sufficient to maintain a pH of from about 5 to about 7.3 upon reconstitution with sterile normal saline or water;wherein the composition is suitable for intramuscular or subcutaneous injection following reconstitution with sterile normal saline or water,wherein the composition is animal protein free, andwherein the composition retains at least about 75% of the theoretical maximum potency of the botulinum toxin following storage as a powder for three months at room temperature.4. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is produced by lyophilization or vacuum-drying.5. The pharmaceutical composition of claim 3 , wherein the botulinum toxin has a molecular weight of about 150 kD.6. The pharmaceutical composition of claim 3 , wherein the surfactant is poloxamer 188.7. The pharmaceutical composition of claim 3 , wherein the disaccharide is sucrose.8. The pharmaceutical composition of claim 3 , wherein the buffer is citrate buffer.9. The pharmaceutical composition of claim 3 , wherein the buffer is an amino acid buffer.10. The pharmaceutical composition of ...

Event-related media management system

An event-related media management system contextualizes media content. The event-related media management system associates media content with contextual event-related data to associate the media content with the events and information about the events. The contextual event-related data can then be used to provide access to the media content, such as through relevant search results or by presenting the media content in organized displays for contextual browsing and navigation. In some embodiments the event-related media management system generates contextualized media content for contextual search, discovery, and advertising.

NON-PROTEIN STABILIZED CLOSTRIDIAL TOXIN PHARMACEUTICAL COMPOSITIONS

A Clostridial toxin pharmaceutical composition comprising a Clostridial toxin, such as a botulinum toxin, wherein the Clostridial toxin present in the pharmaceutical composition is stabilized by a non-protein excipient such as a polyvinylpyrrolidone, a disaccharides, a trisaccharide, a polysaccharide, an alcohol, a metal, an amino acid, a surfactant and/or a polyethylene glycol. 18-. (canceled)9. A lyophilized or vacuum dried pharmaceutical composition comprising:(a) a botulinum toxin, wherein the botulinum toxin is not stabilized by a protein excipient, (b) polyvinylpyrrolidone, and (c) a disaccharide, wherein the potency of the botulinum toxin after reconstitution is at least 40% of the theoretical maximum potency of the botulinum toxin prior to lypophilization.10. The pharmaceutical composition of claim 9 , wherein the botulinum toxin is selected from the group consisting of the botulinum toxins types A claim 9 , B claim 9 , C claim 9 , D claim 9 , E claim 9 , F claim 9 , and G.11. The pharmaceutical composition of claim 9 , wherein the botulinum toxin is a botulinum toxin type A.12. A pharmaceutical composition according to claim 9 , wherein the potency of the botulinum toxin after reconstitution is at least 50% of the theoretical maximum potency of the botulinum toxin prior to lyophilization.13. A pharmaceutical composition according to claim 12 , wherein the potency of the botulinum toxin after reconstitution is at least 60% of the theoretical maximum potency of the botulinum toxin prior to lyophilization.14. A pharmaceutical composition according to claim 13 , wherein the potency of the botulinum toxin after reconstitution is at least 70% of the theoretical maximum potency of the botulinum toxin prior to lyophilization.15. A lyophilized or vacuum dried pharmaceutical composition comprising: (a) a botulinum toxin claim 13 , wherein the botulinum toxin is not stabilized by a protein excipient claim 13 , (b) a compound selected from the group consisting of a ...

HANDSHOWER SLIDE MECHANISM

A handshower slide includes a bar with a passageway, a slide mechanism positioned along a length of the bar, and a showerhead holder movable with the slide mechanism along the length of the bar. The slide mechanism includes a handle and a cam, and the cam is positioned within the passageway and is rotatable between a first orientation and a second orientation relative to the bar. The slide mechanism is not movable along the length of the bar while the cam is in the first orientation and is movable along the length of the bar while the cam is in the second orientation. An orientation of the cam is correlated to a position of the handle, and a spring is coupled to the handle and the cam, so that the spring biases the cam toward the first orientation and away from the second orientation. 1. An adjustable showerhead slide comprising:a bar with a passageway;a slide mechanism positioned along a length of the passageway and at least partially within the passageway; anda showerhead holder movable with the slide mechanism along the length of the passageway,wherein the slide mechanism is not movable along the length of the passageway in a locked configuration and is movable along the length of the passageway in an unlocked configuration, wherein the slide mechanism is biased toward the locked configuration.2. The adjustable showerhead slide of claim 1 , wherein the slide mechanism comprises a handle claim 1 , wherein an orientation of the handle controls whether the slide mechanism is in the unlocked configuration or the locked configuration claim 1 , and wherein claim 1 , when the handle is released claim 1 , the slide mechanism automatically moves into the locked configuration.3. The adjustable showerhead slide of claim 1 , wherein the slide mechanism comprises a cam that is positioned within the passageway and is rotatable between a first orientation and a second orientation relative to the bar claim 1 , wherein the slide mechanism is in the locked configuration while the ...

REGION PROPOSAL NETWORKS FOR AUTOMATED BOUNDING BOX DETECTION AND TEXT SEGMENTATION

Arbitrary image data may be transformed into data suitable for optical character recognition (OCR) processing. A processor may generate a plurality of intermediate feature layers of an image using convolutional neural network (CNN) processing. For each intermediate feature layer, the processor may generate at least one text proposal using a region proposal network (RPN). The at least one text proposal may comprise a portion of the intermediate feature layer that is predicted to contain text. The processor may merge the text proposals with one another to form a patch of the image that is predicted to contain text. The processor may determine outer coordinates of the patch. The outer coordinates may comprise at least leftmost, rightmost, topmost, and bottommost coordinates. The processor may generate a quadrilateral of the image that is a smallest quadrilateral including the leftmost, rightmost, topmost, and bottommost coordinates. 1. A method of transforming arbitrary image data into data suitable for optical character recognition (OCR) processing , the method comprising:generating, by a processor, a plurality of intermediate feature layers of an image using convolutional neural network (CNN) processing;for each intermediate feature layer, generating, by the processor, at least one text proposal using a region proposal network (RPN), the at least one text proposal comprising a portion of the intermediate feature layer that is predicted to contain text;merging, by the processor, the text proposals with one another to form a patch of the image that is predicted to contain text;determining, by the processor, outer coordinates of the patch, the outer coordinates comprising at least leftmost, rightmost, topmost, and bottommost coordinates; andgenerating, by the processor, a quadrilateral of the image that is a smallest quadrilateral including the leftmost, rightmost, topmost, and bottommost coordinates.2. The method of claim 1 , further comprising:defining, by the ...

SINGLE KIDNEY DENERVATION FOR REDUCING AND CONTROLLING HYPERTENSION

Apparatus, systems, and methods provide access to the renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances. 1. A method for inhibiting or modulating the function of renal nerves in a patient's kidney , said method comprising:introducing an effector adjacent to or into an interior of a single kidney or an upper region of a ureter adjacent adjacent to that kidney; andexchanging energy or delivering active substances from the interior of the kidney through a wall of the renal pelvis to renal nerves within the wall of the renal pelvis and surrounding the renal blood vessels in the single kidney without interventing in the patient's other kidney.2. A method as in claim 1 , wherein exchanging energy comprises delivering energy to raise the temperature of the tissue bed surrounding the blood vessels to a temperature in the range from 45° C. to 80° C.3. A method as in claim 2 , wherein the temperature of the papillae claim 2 , the parenchyma claim 2 , and the pyramids in the kidney is maintained below 45° C.4. A method as in claim 1 , wherein exchanging energy comprises extracting energy from the tissue bed surrounding the blood vessels to cool said tissue bed to a temperature in the range from −10° C. to −100° C.5. A method as in claim 4 , wherein the temperature in the tissue beyond that surrounding the renal pelvis including the papillae and the pyramids is maintained above −10° C.6. A method as in claim 1 , wherein introducing comprises advancing the effector through the urinary tract to the renal pelvis.7. A method as in claim 6 , wherein the effector is disposed on a urinary catheter and the urinary catheter is advanced through the urethra ...

EVENT-RELATED MEDIA MANAGEMENT SYSTEM

An event-related media management system contextualizes media content. The event-related media management system associates media content with contextual event-related data to associate the media content with the events and information about the events. The contextual event-related data can then be used to provide access to the media content, such as through relevant search results or by presenting the media content in organized displays for contextual browsing and navigation. In some embodiments the event-related media management system generates contextualized media content for contextual search, discovery, and advertising. 1storing event-related data associated with a plurality of events including a first event;receiving media content items, the media content items including a first media content item;identifying contextual information associated with the first media content item using a computing device;identifying one of the events to which the media content item relates using the contextual information;tagging the event to the first media content item;comparing the contextual information to the event-related data for the identified event; andtagging at least some of the event-related data to the first media content item based at least in part on the comparison of the contextual information to the event-related data.. A method of generating intelligent media content for contextual search, discovery, and advertising, the method comprising: This application is a continuation of U.S. patent application Ser. No. 14/274,199, filed on May 9, 2014, and titled EVENT-RELATED MEDIA MANAGEMENT SYSTEM, and claims priority to U.S. Provisional Application Ser. No. 61/914,955, filed on Dec. 11, 2013, and titled EVENT-RELATED MEDIA MANAGEMENT SYSTEM; and to U.S. Provisional Application Ser. No. 61/902,128, filed on Nov. 8, 2013, and titled EVENT-RELATED MEDIA MANAGEMENT SYSTEM; and to U.S. Provisional Application Ser. No. 61/882,635, filed on Sep. 26, 2013, and titled EVENT- ...

METAMODELING FOR CONFIDENCE PREDICTION IN MACHINE LEARNING BASED DOCUMENT EXTRACTION

A document extraction system executed by a processor, may process documents using manual and automated systems. The document extraction system may efficiently route tasks to the manual and automated systems based on a predicted probability that the results generated by the automated system meet some baseline level of accuracy. To increase document processing speed, documents having a high likelihood of accurate automated processing may be routed to an automated system. To ensure a baseline level of accuracy, documents having a smaller likelihood of accurate automated processing may be routed to a manual system. 1. A method of improving document processing , comprising:acquiring text data from a plurality of documents;generating, by one or more base models included in a machine learning (ML) system, a document type and a set of extraction predictions for each document included in the plurality of documents, the set of extraction predictions including a plurality of text values and a plurality of labels describing the plurality of text values;training a meta model included in the ML system using a training dataset that includes the document type and the extraction predictions for each document included in the plurality of documents;acquiring input text data from a new document;generating, by the one or more base models, a set of extraction predictions for the new document;generating, by the meta model, an extraction confidence prediction for the set of extraction predictions for the new document;evaluating the accuracy of the set of extraction predictions for the new document by comparing the extraction confidence prediction to a confidence threshold; andin response to determining the extraction confidence prediction is above a confidence threshold, arranging the new document to be automatically extracted using the set of extraction predictions for the new document.2. The method of claim 1 , wherein the training further comprises:generating a ground truth dataset ...

METHODS AND SYSTEMS FOR ABLATION OF THE RENAL PELVIS

Apparatus, systems, and methods provide access to the renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances to ablate a thin layer of tissue lining at least a portion of the renal pelvis to disrupt renal nerves within the tissue lining of the renal pelvis 1. A method for delivering energy to a renal pelvis , said method comprising:introducing a wire into the ureter adjacent to or within the renal pelvis, wherein said wire has a pre-shaped distal region configured to conform to the renal pelvis;advancing the distal portion of the wire into the renal pelvis, wherein the distal portion is radially constrained while being advanced;releasing the distal region of the wire to engage tissue over a wall of the renal pelvis; andapplying energy to the wall of the renal pelvis through a plurality of electrodes on the wire, wherein the electrodes have rounded surfaces which extend beyond the surface of the adjacent wire and which embed into the wall.2. A method for delivering energy to a renal pelvis as in claim 1 , further comprising applying a vacuum within the renal pelvis while applying energy to draw the walls of the renal pelvis against the rounded electrodes.3. A method for delivering energy to a renal pelvis as in claim 1 , wherein the pre-shaped distal region of the wire has a helical or spiral distal geometry.4. A method for delivering energy to a renal pelvis as in claim 1 , wherein the pre-shaped distal region of the wire has a looped distal end.5. A method for delivering energy to a renal pelvis as in claim 1 , wherein at least the pre-shaped distal region of the wire is electrically insulated over its surface between the electrodes.6. A ...

Hanger system with hanger coupling member

A hanger assembly includes a primary hanger, an auxiliary hanger, and a coupling member. The primary hanger includes a hook configured to selectively receive a support rod, a pair of arms coupled to the hook and extending outwardly therefrom to form two, opposite free arm ends. The pair of arms defines an interior coupling cavity extending into an interior of the pair of arms upwardly from bottom edges of the pair of arms. The auxiliary hanger is configured to support a garment. The coupling member defines a first end and a second end opposite and spaced from the first end. The first end of the coupling member includes a first clip selectively secured within the interior coupling cavity of the primary hanger substantially above the bottom edges of the pair of arms. The second end of the coupling member is secured to the auxiliary hanger.

EVENT-RELATED MEDIA MANAGEMENT SYSTEM

An event-related media management system contextualizes media content. The event-related media management system associates media content with contextual event-related data to associate the media content with the events and information about the events. The contextual event-related data can then be used to provide access to the media content, such as through relevant search results or by presenting the media content in organized displays for contextual browsing and navigation. In some embodiments the event-related media management system generates contextualized media content for contextual search, discovery, and advertising. 120-. (canceled)21. A non-transitory computer-readable medium storing data instructions , which when executed by a processing device of a mobile computing device , cause the processing device to:transmit contextual information associated with a media content item from the mobile computing device to a server computing device, wherein the media content item was captured by a digital camera of the mobile computing device;receive, from the server computing device: (i) event data identifying a particular event associated with the media content item based at least in part on the contextual information; and(ii) event segment data identifying an event segment of the particular event that is associated with the media content item based at least in part on the contextual information;display a user interface on a touch sensitive display device of the mobile computing device, the user interface displaying the media content item and a special effects control, wherein the special effects control is selectable to apply a special effect to the media content item to modify an appearance of the media content item;receive a touch input into the user interface via the touch sensitive display device to select the special effects control;apply a special effect associated with the special effects control to the media content item to modify the appearance of the media ...

RACK ASSEMBLY STRUCTURE

Embodiments of the present disclosure provide techniques and configurations for a rack assembly. In one embodiment, a tray to be disposed in a rack assembly may comprise a plurality of sleds with individual sleds including one or more compute nodes; and a networking element coupled with a sled of the plurality of sleds and configured to communicatively connect the sled to one or more other components of the rack assembly via an optical communication system. The optical communication system may include an external optical cable configured to communicatively connect the networking element with the rack assembly. Other embodiments may be described and/or claimed. 1. A rack assembly , comprising:a tray, having at least one sled including at least one compute node, and a midplane coupled with the sled, to provide connectivity for the sled;an optical patch panel coupled with the midplane via an optical communication system, wherein the optical communication system includes an optical module that resides on the midplane, an optical jumper cable coupled with the optical module, and an external optical cable coupled with the optical jumper cable and the optical patch panel; anda top of rack (TOR) switch coupled with the optical patch panel, wherein the optical patch panel is to provide connectivity between the tray and the TOR switch of the rack assembly.2. The rack assembly of claim 1 , further comprising a mezzanine card attached to the midplane claim 1 , to provide connectivity between the sled and the optical patch panel claim 1 , to enable transmission and reception of optical data streams claim 1 , wherein the optical module is coupled with the mezzanine card.3. The rack assembly of claim 2 , wherein the mezzanine card includes a central processing unit (CPU) control module claim 2 , and a switch coupled with the optical module.4. The rack assembly of claim 1 , wherein the optical patch panel comprises one or more optical channels to provide optical connections between ...

METHODS AND DEVICES FOR TREATING POLYCYSTIC KIDNEY DISEASE AND ITS SYMPTOMS

Apparatus, systems, and methods for treating PKD by providing access to a patient's renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances to ablate a thin layer of tissue lining at least a portion of the renal pelvis to disrupt renal nerves within the tissue lining of the renal pelvis 1. A method for treating PKD , the method comprising:selecting a patient diagnosed with PKD;positioning a distal end of a catheter into an interior of the patient's kidney; anddelivering an amount of energy through a wall of the kidney to denervate adjacent nerves to treat the PKD.2. A method as in claim 1 , wherein the energy is RF energy delivered via one or more flexible wires on the distal end of the catheter.3. A method as in claim 2 , wherein the one or more flexible wires are manipulable between a first position wherein the one or more flexible wires are within the lumen claim 2 , and a second position wherein the one or more flexible wires are extended out of the lumen through the opening.4. A method as in claim 3 , wherein the one or more flexible wires are configured to deliver energy to the renal nerve when the one or more flexible wires are in the second position.5. A method as in claim 2 , wherein the catheter is inserted to the first position within the conduit claim 2 , the first distal end is positioned adjacent to a renal nerve claim 2 , the one or more flexible wires are through the lumen or the catheter is retracted so that the one or more flexible wires extend out of the lumen through the opening adjacent the renal nerve. This application is a continuation-in-part of U.S. patent application Ser. No. 15/979,222 (Attorney Docket No. 42532- ...

EVENT-RELATED MEDIA MANAGEMENT SYSTEM

An event-related media management system contextualizes media content. The event-related media management system associates media content with contextual event-related data to associate the media content with the events and information about the events. The contextual event-related data can then be used to provide access to the media content, such as through relevant search results or by presenting the media content in organized displays for contextual browsing and navigation. In some embodiments the event-related media management system generates contextualized media content for contextual search, discovery, and advertising. 1. A method of generating intelligent media content for contextual search , discovery , and advertising , the method comprising:storing event-related data associated with a plurality of events including a first event;receiving media content items, the media content items including a first media content item;identifying contextual information associated with the first media content item using a computing device;identifying one of the events to which the media content item relates using the contextual information;tagging the event to the first media content item;comparing the contextual information to the event-related data for the identified event; andtagging at least some of the event-related data to the first media content item based at least in part on the comparison of the contextual information to the event-related data.2. The method of claim 1 , wherein the event-related data includes event segment data identifying segments of the event claim 1 , the method further comprising:identifying event segment data associated with a segment of the event to which the first media content relates, by comparing the contextual information with the event-related data; andtagging the first media content with the event segment based at least in part on the comparison.3. The method of claim 2 , wherein the event segment is a scored segment.4. The method of ...

PHARMACEUTICAL COMPOSITIONS CONTAINING BOTULINUM NEUROTOXIN

This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D. 1. A pharmaceutical composition , comprising: (a) a botulinum toxin , and (b) a recombinant human serum albumin , wherein the pharmaceutical composition is in a lyophilized or vacuum-dried condition for reconstitution.2. (canceled)3. The pharmaceutical composition of claim 1 , further comprising an acetyltryptophanate or salts or derivatives thereof.4. The pharmaceutical composition of claim 1 , wherein the recombinant human serum albumin was expressed in yeast cells.5. The pharmaceutical composition of claim 1 , wherein the botulinum toxin is botulinum toxin type A. This application is a continuation of U.S. application Ser. No. 13/933,723, filed Jul. 2, 2013, which is a continuation of U.S. application Ser. No. 13/467,795, filed May 9, 2012, now U.S. Pat. No. 8,501,196, which is a divisional of application Ser. No. 11/539,778, filed Oct. 9, 2006, now U.S. Pat. No. 8,216,591, which is a divisional of application Ser. No. 11/303,000, filed Dec. 13, 2005, now U.S. Pat. No. 7,758,873, which is a continuation of application Ser. No. 10/359,828, filed Feb. 7, 2003, now U.S. Pat. No. 7,780,967, which is a continuation in part of application Ser. No. 10/288,738, filed Nov. 5, 2002 (now abandoned), which is a continuation in part of application Ser. No. 10/047,058, filed Jan. 14, 2002 (now abandoned), which is a continuation in part of application Ser. No. 09/500,147, filed Feb. 8, 2000 (now abandoned). The entire contents of these prior patent applications are incorporated herein by reference.This invention relates to pharmaceutical compositions comprising a polysaccharide and a botulinum toxin, and uses thereof, such as to treat a facial ...

HANGER WITH SECUREMENT ELEMENT

A garment hanger includes a hook and an arm. The hook is configured to receive a support rod, and the arm is coupled to the hook and extends outwardly to a free arm end. The arm includes a first substantially planar panel and a top panel extending rearwardly from a top edge of the first substantially planar panel. The arm further includes an indentation and a finger. The indentation is defined adjacent the first substantially planar panel to be at least partially open in a direction facing away from the first substantially planar panel. The indentation defines an outermost edge nearest the free arm end and an innermost end nearest the hook. The finger extends from one of the outermost edge and the innermost edge of the indentation toward the other and is configured to hold a portion of a garment within the indentation. 1. A garment hanger comprising:a hook configured to selectively receive a support rod; a first substantially planar panel facing toward one of a front and a rear of the garment hanger,', 'a top panel extending rearwardly from a top edge of the first substantially planar panel,', 'an indentation defined adjacent the first substantially planar panel and below the top panel to be at least partially open in a direction facing away from the first substantially planar panel, the indentation defining an outermost edge nearest the free arm end and an innermost end nearest the hook, and', 'a finger extending from one of the outermost edge and the innermost edge of the indentation toward the other one of the outermost edge and the innermost edge of the indentation and being configured to hold a portion of a garment within the indentation, wherein the finger is formed adjacent the indentation opposite the first substantially planar panel., 'an arm coupled to the hook and extending outwardly to a free arm end, wherein the arm includes2. The garment hanger of claim 1 , wherein the finger defines an exterior-facing surface opposite the indentation claim 1 , and the ...

EVENT-RELATED MEDIA MANAGEMENT SYSTEM

An event-related media management system contextualizes media content. The event-related media management system associates media content with contextual event-related data to associate the media content with the events and information about the events. The contextual event-related data can then be used to provide access to the media content, such as through relevant search results or by presenting the media content in organized displays for contextual browsing and navigation. In some embodiments the event-related media management system generates contextualized media content for contextual search, discovery, and advertising. 1. A method of automatically generating tags for media content , the method comprising:storing event-related data associated with at least one event including a particular event in at least one computer readable storage device, the event-related data including discrete action data identifying discrete actions that occur during the particular event including a particular discrete action;identifying contextual information associated with a particular media content item using the at least one computing device;determining that the particular media content item relates to the particular event of the at least one event based at least in part on the contextual information, using the at least one computing device;automatically generating a tag identifying the particular event for the particular media content item using the at least one computing device;comparing the contextual information to the discrete action data for the particular event to identify a relationship between the particular media content item and the particular discrete action; andautomatically generating a tag identifying the particular discrete action of the particular event as a result of the identified relationship between the particular media content item and the particular discrete action.2. The method of claim 1 , further comprising generating and storing a text-based message ...

Apparatus and Process for Liquefying Gases

A liquefier device which may be a retrofit to an air separation plant or utilized as part of a new design. The flow needed for the liquefier comes from an air separation plant running in a maxim oxygen state, in a stable mode. The three gas flows are low pressure oxygen, low pressure nitrogen, and higher pressure nitrogen. All of the flows are found on the side of the main heat exchanger with a temperature of about 37 degrees Fahrenheit. All of the gasses put into the liquefier come out as a subcooled liquid, for storage or return to the air separation plant. This new liquefier does not include a front end electrical compressor, and will take a self produced liquid nitrogen, pump it up to a runnable 420 psig pressure, and with the use of turbines, condensers, flash pots, and multi pass heat exchangers. The liquefier will make liquid from a planned amount of any pure gas oxygen or nitrogen an air separation plant can produce. 1. A liquefier device for producing liquid oxygen and liquid nitrogen comprising:a plurality of multi-pass counter current flow heat exchangers including an oxygen cooler, a nitrogen bath boiler, a preheater for heating a vaporized nitrogen flow produced by the boiler, a condenser, an added cooling heat exchanger,the oxygen cooler, boiler, and condenser configured for cooling the oxygen gas flow prior to entering an oxygen production flash pot for converting the oxygen gas flow to subcooled liquid oxygen,a turbine assembly having a plurality of turbine expanders connected in parallel and exiting to a common header, and a plurality of turbine boosters connected in series each having an associated aftercooler,the turbine boosters connected in series configured to produce a major flow of compressed nitrogen gas which major flow provides a warming nitrogen flow to the oxygen cooler, the preheater, and a bypass valve, said warming nitrogen flows rejoining prior to entering the boiler, and then cooling to a two-phase liquid gas nitrogen stream in the ...

Composition and method for hydrocarbon and lipid degradation and dispersal

The present invention is directed toward a bioremediation product, its method of manufacture and method of use. A blend of microorganisms, cleansers and surfactants is disclosed which is non-toxic and solvent free, and which has the ability to accelerate the breaking down process of oils, materials such as benzene, toluene, and xylene (BTEX); petroleum hydrocarbon fractions F1-F4 (as defined by CCME2000), polycyclic aromatic hydrocarbons (PAH), paraffin waxes, volatile organics, molds, and the like; while simultaneously providing a biological component which is effective to reduce the total petroleum hydrocarbon levels to zero at an accelerated rate. The product is useful for bioremediation and as an oil dispersant composition useful in treating oil spills, and for cleanup of the shoreline, animals, plants, and equipment.

SUSTAINED RELEASE POLOXAMER CONTAINING PHARMACEUTICAL COMPOSITIONS

A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system from which the biologically active botulinum toxin is released over a multi-day period thereby localizing the drug as a depot and controlling release to enhance the therapeutic effect per dose. 1. A thermoreversible , thermoplastic , pharmaceutical composition consisting of: (a) a biologically active botulinum toxin , and; (b) a thermoplastic poloxamer , wherein the thermoreversible , thermoplastic , pharmaceutical composition is transitionable from a low viscosity liquid solution for easy passage through a needle prior to administration by injection to a patient to a gel after administration.2. The pharmaceutical composition of claim 1 , wherein the poloxamer is a poloxamer 407.3. The pharmaceutical composition of claim 1 , wherein the biologically active botulinum toxin is a botulinum toxin type A.4. The pharmaceutical composition of claim 1 , wherein the biologically active botulinum toxin is a botulinum toxin type B.5. The pharmaceutical composition of claim 1 , wherein the biologically active botulinum toxin is a neurotoxic component of a botulinum toxin.6. A thermoreversible claim 1 , thermoplastic claim 1 , gelable claim 1 , pharmaceutical composition made by a process consisting of the steps of: a) dissolving a thermo-reversible thermoplastic poloxamer in a solvent at a temperature below about 37 degrees Centigrade until dissolved; and b) adding and mixing a botulinum toxin and an additional ingredient selected from the group consisting of polysorbate claim 1 , a second polaxamer claim 1 , dextran claim 1 , histidine claim 1 , citrate buffer claim 1 , isopropyl myristate ...

PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF

Processes for the preparation of certain isoindole compounds, and isotopologues thereof, are provided. In some embodiments, the processes comprise catalytic assymetrical hydrogenation with hydrogen gas or deuterium gas in a solvent containing exchangeable proton or deuterium for proton-deuterium exchange. 125-. (canceled)27. The process of claim 26 , wherein Yis hydrogen or deuterium; and Yand Yare both hydrogen or both deuterium.28. The process of claim 27 , wherein Yis hydrogen or deuterium; and Yand Yare both hydrogen or both deuterium claim 27 , wherein not all of Y claim 27 , Y claim 27 , and Yare hydrogen.30. The process of claim 26 , wherein Rand Rare substituted or unsubstituted (C-C)alkoxy claim 26 , or an isotopologue thereof.31. The process of claim 30 , wherein Ris OMe enriched with 0 claim 30 , 1 claim 30 , 2 claim 30 , or 3 deuterium claim 30 , and Ris OEt enriched with 0 claim 30 , 1 claim 30 , 2 claim 30 , 3 claim 30 , 4 claim 30 , or 5 deuterium.32. The process of claim 31 , wherein Ris OCD claim 31 , and Ris OEt.33. The process of claim 31 , wherein Ris OCD claim 31 , and Ris OCDCD.34. The process of claim 26 , wherein Ris Me enriched with 0 claim 26 , 1 claim 26 , 2 claim 26 , or 3 deuterium.37. The process of claim 26 , wherein the hydrogenation in step (a) occurs with hydrogen gas.38. The process of claim 26 , wherein the hydrogenation in step (a) occurs with deuterium gas.39. The process of claim 26 , wherein the hydrogenation in step (a) occurs in a solvent containing exchangeable proton for proton-deuterium exchange.40. The process of claim 39 , wherein the solvent containing exchangeable proton for proton-deuterium exchange is 2 claim 39 ,2 claim 39 ,2-trifluoroethanol.41. The process of claim 26 , wherein the hydrogenation in step (a) occurs in a solvent containing exchangeable deuterium for proton-deuterium exchange.42. The process of claim 41 , wherein the solvent containing exchangeable deuterium for proton-deuterium exchange is 2 claim ...

METHOD FOR SERVING PARAMETER EFFICIENT NLP MODELS THROUGH ADAPTIVE ARCHITECTURES

A machine learning system executed by a processor may generate predictions for a variety of natural language processing (NLP) tasks. The machine learning system may include a single deployment implementing a parameter efficient transfer learning architecture. The machine learning system may use adapter layers to dynamically modify a base model to generate a plurality of fine-tuned models. Each fine-tuned model may generate predictions for a specific NLP task. By transferring knowledge from the base model to each fine-tuned model, the ML system achieves a significant reduction in the number of tunable parameters required to generate a fine-tuned NLP model and decreases the fine-tuned model artifact size. Additionally, the ML system reduces training times for fine-tuned NLP models, promotes transfer learning across NLP tasks with lower labeled data volumes, and enables easier and more computationally efficient deployments for multi-task NLP. 1. A method for providing a variety of natural language processing (NLP) models , comprising:receiving a first input data comprising a first input text and a first task type, the first task type specifying one or more target NLP task types to be performed on the first input text;generating a first model tuned to generate predictions for a first NLP task having the first task type, the generating comprising integrating, into a base model, a first model artifact comprising one or more adapter layers specific to the first task type;generating, based on processing the first input text with the first model, a prediction for the first NLP task; andproviding the prediction to one or more application instances.2. The method of claim 1 , wherein the base model comprises one or more encoder layers that process training data to generate base parameters.3. The method of claim 2 , further comprising:training the base parameters, the training comprising:tokenizing one or more corpora of text data to generate a plurality of tokens;generating ...

SYSTEMS AND METHODS FOR SANDING A SURFACE OF A STRUCTURE

A system for sanding a surface includes a sanding tool, a robotic manipulator to move the sanding tool relative to the surface, and a control unit operatively coupled with the sanding tool and the robotic manipulator. The control unit is operable to: (1) move the sanding tool to a sanding position relative to the surface in which an abrasive surface is in contact with the surface and a sanding force is approximately normal to the surface; (2) set one or more sanding parameters corresponding to a model material removal rate; (3) monitor one or more of the sanding parameters; (4) determine an actual material removal rate, based on one or more of the sanding parameters being monitored; and (5) modify one or more of the sanding parameters until the actual material removal rate is approximately equal to the model material removal rate. 1. A system for sanding a surface of a structure , the system comprising:a sanding tool comprising an abrasive surface;a robotic manipulator coupled to the sanding tool and configured to move the sanding tool relative to the structure; and move the sanding tool to a sanding position relative to the surface of the structure using the robotic manipulator, in which the abrasive surface is in contact with the surface and a sanding force, applied to the surface of the structure by the sanding tool, is approximately normal to the surface;', 'set one or more sanding parameters corresponding to a model material removal rate;', 'monitor one or more of the sanding parameters when the sanding tool is in the sanding position;', 'determine an actual material removal rate, based on one or more of the sanding parameters being monitored; and', 'modify one or more of the sanding parameters until the actual material removal rate is approximately equal to the model material removal rate., 'a control unit operatively coupled with the sanding tool and the robotic manipulator, wherein the control unit is operable to2. The system of claim 1 , further comprising ...

MULTI-STAGE SHOCK ABSORBER

A jounce control damping system with an elongated housing containing a damping medium, a primary piston assembly, a moveable outer piston assembly, and a movable inner piston assembly disposed at least partially within the outer piston assembly. The primary piston assembly provides a first compression damping force. The inner piston engages the primary piston assembly and provides a second compression damping force when moved in a compression direction. After the inner piston assembly moves a given distance, the outer piston assembly is moved in the compressive direction and provides a third compression damping force. 1. A jounce control damping system comprising:an elongated housing containing a damping medium;a moveable outer piston assembly disposed within the housing;a movable inner piston assembly disposed at least partially within the outer piston assembly;said inner piston assembly being configured to engage a primary piston assembly as said primary piston assembly is moved beyond a first compression movement distance causing the inner piston assembly to move in the compressive direction; andsaid outer piston assembly being configured to move in the compressive direction in response to the inner piston assembly moving in the compressive direction beyond a second compressive movement distance,wherein the primary piston assembly provides a first compression damping force during the first compression movement distance of the primary piston;wherein the inner piston assembly provides a second compression damping force during the second compression movement distance of the inner piston assembly and the outer piston assembly provides a third compression damping force greater than the second compression damping force during the third compression movement distance.2. The system of claim 1 , wherein the inner piston assembly comprises an element for engaging the primary piston assembly.3. The system of claim 2 , wherein said element comprises at least one aperture that ...

EVENT-RELATED MEDIA MANAGEMENT SYSTEM

An event-related media management system contextualizes media content. The event-related media management system associates media content with contextual event-related data to associate the media content with the events and information about the events. The contextual event-related data can then be used to provide access to the media content, such as through relevant search results or by presenting the media content in organized displays for contextual browsing and navigation. In some embodiments the event-related media management system generates contextualized media content for contextual search, discovery, and advertising. 1. A method of generating intelligent media content for contextual search , discovery , and advertising , the method comprising:storing event-related data associated with a plurality of events including a first event;receiving media content items, the media content items including a first media content item;identifying contextual information associated with the first media content item using a computing device;identifying one of the events to which the media content item relates using the contextual information;tagging the event to the first media content item;comparing the contextual information to the event-related data for the identified event; andtagging at least some of the event-related data to the first media content item based at least in part on the comparison of the contextual information to the event-related data.2. The method of claim 1 , wherein the event-related data includes event segment data identifying segments of the event claim 1 , the method further comprising:identifying event segment data associated with a segment of the event to which the first media content relates, by comparing the contextual information with the event-related data; andtagging the first media content with the event segment based at least in part on the comparison.3. The method of claim 2 , wherein the event segment is a scored segment.4. The method of ...

EVENT-RELATED MEDIA MANAGEMENT SYSTEM

An event-related media management system contextualizes media content. The event-related media management system associates media content with contextual event-related data to associate the media content with the events and information about the events. The contextual event-related data can then be used to provide access to the media content, such as through relevant search results or by presenting the media content in organized displays for contextual browsing and navigation. In some embodiments the event-related media management system generates contextualized media content for contextual search, discovery, and advertising. 1. A method of automatically generating tags for media content , the method comprising:storing event-related data associated with at least one sports event including a particular sports event in at least one computer readable storage device, the event-related data including discrete action data identifying discrete actions that occur during the particular sports event including a particular discrete action;identifying contextual information associated with a particular media content item using the at least one computing device;determining that the particular media content item relates to the particular sports event of the at least one sports event based at least in part on the contextual information, using the at least one computing device;automatically generating a tag identifying the particular sports event for the particular media content item using the at least one computing device;comparing the contextual information to the discrete action data for the particular sports event to identify a relationship between the particular media content item and the particular discrete action; andautomatically tagging the particular media content item with a tag identifying the particular discrete action of the particular sports event as a result of the identified relationship between the particular media content item and the particular discrete action ...

CONTAINER ASSEMBLY WITH LOCKING CLOSURE

A container assembly comprising a container and a closure. The container includes a body defining a storage chamber and a neck. The neck extends away from the body and defines an open mouth providing access to the storage chamber. The neck further defines an exterior surface and at least two latching protrusions extending radially outwardly from the exterior surface. The closure includes a top wall, a cylindrical wall extending downwardly from the top wall, a first lug extending radially inwardly from the cylindrical wall, and a second lug extending radially inwardly from the cylindrical wall. A top surface of the first lug and a top surface of the second lug are each positioned a substantially identical distance away from the top wall and the first lug and the second lug are each configured to selectively lock with a common one of the at least two latching protrusions. 1. A container assembly comprising: the body defines a storage chamber,', 'the neck extends away from the body and defines an open mouth providing access to the storage chamber, and', 'the neck defines an exterior surface and at least two latching protrusions extending radially outwardly from the exterior surface; and, 'a container including a body and a neck, whereina closure including a top wall, a cylindrical wall extending downwardly from the top wall, a first lug extending radially inwardly from the cylindrical wall, and a second lug extending radially inwardly from the cylindrical wall, wherein a top surface of the first lug and a top surface of the second lug are each positioned a substantially identical distance away from the top wall and the first lug and the second lug are each configured to selectively lock with a common one of the at least two latching protrusions.2. The container assembly of claim 1 , wherein:the first lug and the second lug collectively form a pair of lugs,the container assembly includes two or more pairs of lugs, andeach of the two or more pairs of lugs interfaces with ...

BOTULINUM TOXIN FORMULATION

neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the toxin at a subdermal location and fewer toxin induced complications or side effects. 1botulinumbotulinumbotulinumbotulinum. A method for treating a disease or condition in a human patient by administering to the patient a pharmaceutical composition comprising a neurotoxin , albumin and a viscous carrier for the neurotoxin , wherein the viscous carrier comprises a cross-linked hyaluronic acid having a molecular weight ranging from about 10 ,000 daltons to about 200 ,000 daltons , a crosslinking density ranging from about 5% to about 10% , present in an range from about 1% to about 4% (w/v) of the pharmaceutical composition , wherein the pharmaceutical composition having a viscosity range from about 100 cps to about 1 ,000 cps at a sheer rate 0.1/second at 25° C.; and wherein the patient experiences significantly fewer complications due to the toxin than occur upon administration of a toxin containing pharmaceutical composition which does not comprise a viscous carrier.2. The method of claim 1 , wherein the administering is carried out by local subdermal injection of the pharmaceutical composition.3. The method of claim 1 , wherein the disease or condition is selected from the group of diseases and conditions consisting of dystonia claim 1 , cervical dystonia claim 1 , blepharospasm claim 1 , strabismus claim 1 , spasticity claim 1 , movement disorder claim 1 , headache claim 1 , migraine claim 1 , hyperhydrosis claim 1 , overactive bladder claim 1 , prostate disorder claim 1 , articular pathology claim 1 , arthritis claim 1 , facial wrinkles claim 1 , and glabellar lines.4. The method of claim 1 , wherein the complications are local complications selected from the group of local complications consisting of ptosis claim 1 , brow ptosis claim 1 , visual field impairment claim 1 , double vision claim 1 , ectropion claim 1 , tearing claim 1 , asymmetric facial expression claim 1 , ...

Methods and systems for ablation of the renal pelvis

Apparatus, systems, and methods provide access to the renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances to ablate a thin layer of tissue lining at least a portion of the renal pelvis to disrupt renal nerves within the tissue lining of the renal pelvis.

METHOD OF SUPPLYING INVENTORY

A method of supplying inventory includes sorting inventory into flexible inventory bags or soft-sided containers. Each flexible inventory bag or soft-sided container that receives the inventory corresponds with a final desired location in a building of a retailer. Each flexible inventory bag or soft-sided container is transported to the final desired location and inventory from the flexible inventory bag or soft-sided container is set into the final desired location. 1. A method of supplying inventory comprising:sorting inventory into flexible inventory bags, each flexible inventory bag that receives the inventory corresponds with a final desired location in a building of a retailer;loading the flexible inventory bags onto a vehicle;shipping the flexible inventory bags from a warehouse to the building on the vehicle;unloading the flexible inventory bags from the vehicle into the building;moving each flexible inventory bag to the final desired location in the building; andsetting inventory from each flexible inventory bag in the final desired location.2. The method of claim 1 , wherein the final desired location is an aisle in the building.3. The method of claim 2 , wherein the final desired location is a section of the aisle in the building.4. The method of claim 1 , wherein loading the flexible inventory bags onto a vehicle comprises hanging the flexible inventory bags on movable carts and loading the movable carts onto the vehicle for shipping.5. The method of claim 4 , wherein unloading the flexible inventory bags from the vehicle comprises unloading the movable carts from the vehicle.6. The method of claim 5 , wherein moving each flexible inventory bag to the final desired location comprises transporting the movable carts to the final desired location.7. The method of claim 1 , wherein setting inventory from each flexible inventory bag in the final desired location comprises carrying the flexible inventory bag to set inventory from the flexible inventory bag.8. ...

HANDSHOWER SLIDE MECHANISM

A handshower slide comprising a bar with a passageway and a slide mechanism positioned along a length of the bar. The slide mechanism comprises a handle, a cam, and a shower holder. The cam is positioned within the passageway and is rotatable between a first orientation and a second orientation relative to the bar. The slide mechanism is secured along the length of the bar while the cam is in the first orientation and movable along the length of the bar while the cam is in the second orientation. An orientation of the cam is controlled by a spring and is biased toward the first orientation. The handle is coupled the slide mechanism through the spring and an orientation of the cam is correlated to a position of the handle. The cam is movable from the first orientation to the second orientation by an external force on the handle. 1. A handshower slide comprising:a bar with a passageway; and wherein the slide mechanism comprises a handle, a cam, and a shower holder,', 'wherein the cam is positioned within the passageway and is rotatable between a first orientation and a second orientation relative to the bar,', 'wherein the slide mechanism is secured along the length of the bar while the cam is in the first orientation and movable along the length of the bar while the cam is in the second orientation,', 'wherein an orientation of the cam is controlled by a spring and is biased toward the first orientation,', 'wherein the handle is coupled the slide mechanism through the spring and an orientation of the cam is correlated to a position of the handle, and', 'wherein the cam is configured to be movable from the first orientation to the second orientation by an external force on the handle that overcomes the force of the spring and frictionally engages the cam with the bar., 'a slide mechanism positioned along a length of the bar,'}2. The handshower slide of claim 1 , further comprising at least one gripping material on an outside perimeter of the cam.3. The handshower ...

BOTULINUM TOXIN COMPOSITIONS

A high potency botulinum toxin pharmaceutical composition comprising two excipients (such as albumin and sodium chloride) in a weight to weight ratio of between about 1 and about 100. 1. A pharmaceutical composition comprising:(a) a botulinum toxin;(b) a first excipient, wherein the first excipient is an albumin, and;(c) a second excipient, wherein the second excipient is sodium chloride;(d) wherein the weight to weight ratio of the first excipient to the second excipient present in the pharmaceutical composition is between 0.7 and 5.6, or between 7.4 and 55.6.2. The pharmaceutical composition of claim 1 , wherein the botulinum toxin is present as a botulinum toxin complex.3. The pharmaceutical composition of claim 1 , wherein the botulinum toxin is present as a pure botulinum toxin.4. The pharmaceutical composition of claim 1 , wherein the first excipient is a serum albumin.5. The pharmaceutical composition of claim 1 , wherein the first excipient is recombinant albumin.6. A process for making a pharmaceutical composition claim 1 , the process comprising the step of:(a) combining about 2.5 ng of a botulinum toxin type A complex with an albumin and sodium chloride in a weight to weight ration of the albumin to the sodium chloride in the pharmaceutical composition of between 0.7 and 5.6, or between 7.4 and 55.6, to form a mixture, and;(b) vacuum drying the mixture, to thereby obtain a pharmaceutical composition with a potency after reconstitution of between about 70 units and about 130 units.7. The process of claim 6 , further comprising the step claim 6 , before the vacuum drying step claim 6 , lyophilizing the mixture.8. The pharmaceutical composition obtainable by the process of . This application is a continuation of U.S. application Ser. No. 14/055,749, which was filed on Oct. 16, 2013, now U.S. Pat. No. 9,629,904, which is a continuation of U.S. application Ser. No. 13/566,804 filed Aug. 3, 2012, now U.S. Pat. No. 8,580,250, which is a continuation of U.S. ...

EVENT-RELATED MEDIA MANAGEMENT SYSTEM

An event-related media management system contextualizes media content. The event-related media management system associates media content with contextual event-related data to associate the media content with the events and information about the events. The contextual event-related data can then be used to provide access to the media content, such as through relevant search results or by presenting the media content in organized displays for contextual browsing and navigation. In some embodiments the event-related media management system generates contextualized media content for contextual search, discovery, and advertising. 120-. (canceled)21. A non-transitory computer-readable medium storing data instructions , which when executed by a processing device of a mobile computing device , cause the mobile computing device to:transmit contextual information associated with a media content item from the mobile computing device to a server computing device, wherein the media content item was captured by a digital camera of the mobile computing device;receive, from the server computing device: (i) event data identifying a particular event associated with the media content item based at least in part on the contextual information; and (ii) event segment data identifying an event segment of the particular event that is associated with the media content item based at least in part on the contextual information;display a user interface on a touch sensitive display device of the mobile computing device, the user interface displaying the media content item and a special effects control, wherein the special effects control is selectable to apply a special effect to the media content item to modify an appearance of the media content item;receive a touch input into the user interface via the touch sensitive display device to select the special effects control;apply the special effect associated with the special effects control to the media content item to modify the appearance of ...

EVENT-RELATED MEDIA MANAGEMENT SYSTEM

An event-related media management system contextualizes media content. The event-related media management system associates media content with contextual event-related data to associate the media content with the events and information about the events. The contextual event-related data can then be used to provide access to the media content, such as through relevant search results or by presenting the media content in organized displays for contextual browsing and navigation. In some embodiments the event-related media management system generates contextualized media content for contextual search, discovery, and advertising. 1. A method of generating intelligent media content for contextual search , discovery , and advertising , the method comprising:storing event-related data associated with a plurality of events including a first event;receiving media content items, the media content items including a first media content item;identifying contextual information associated with the first media content item using a computing device;identifying one of the events to which the media content item relates using the contextual information;tagging the event to the first media content item;comparing the contextual information to the event-related data for the identified event; andtagging at least some of the event-related data to the first media content item based at least in part on the comparison of the contextual information to the event-related data.2. The method of claim 1 , wherein the event-related data includes event segment data identifying segments of the event claim 1 , the method further comprising:identifying event segment data associated with a segment of the event to which the first media content relates, by comparing the contextual information with the event-related data; andtagging the first media content with the event segment based at least in part on the comparison.3. The method of claim 2 , wherein the event segment is a scored segment.4. The method of ...

Supervised machine learning algorithm application for image cropping and skew rectification

Systems and methods here may be used for pre-processing images, including using a computer for receiving a pixelated image of a paper document of an original size, downscaling the received pixelated image, employing a neural network algorithm to the downscaled image to identify four corners of the paper document in the received pixelated image, re-enlarging the downscaled image to the original size, identifying each of four corners of the paper document in the pixelated image, determining a quadrilateral composed of lines that intersect at four angles at the four corners of the paper document in the pixelated image, defining a projective plane of the pixelated image, and determining an inverse transformation of the pixelated image to transform the projective plane quadrilateral into a right angled rectangle.

System and method for information extraction with character level features

A system and method for information extraction character level features. The system and method may be used for data extraction for various types of content including a receipt or a tax form.

MULTI-STAGE SHOCK ABSORBER

A jounce control damping system with an elongated housing containing a damping medium, a primary piston assembly, a moveable outer piston assembly, and a movable inner piston assembly disposed at least partially within the outer piston assembly. The primary piston assembly provides a first compression damping force. The inner piston engages the primary piston assembly and provides a second compression damping force when moved in a compression direction. After the inner piston assembly moves a given distance, the outer piston assembly is moved in the compressive direction and provides a third compression damping force. 1. A jounce control damping system comprising:an elongated housing containing a damping medium;a moveable outer piston assembly disposed within the housing;a movable inner piston assembly disposed at least partially within the outer piston assembly;said inner piston assembly being configured to engage a primary piston assembly as said primary piston assembly is moved beyond a first compression movement distance causing the inner piston assembly to move in the compressive direction; andsaid outer piston assembly being configured to move in the compressive direction in response to the inner piston assembly moving in the compressive direction beyond a second compressive movement distance,wherein the primary piston assembly provides a first compression damping force during the first compression movement distance of the primary piston;wherein the inner piston assembly provides a second compression damping force during the second compression movement distance of the inner piston assembly and the outer piston assembly provides a third compression damping force greater than the second compression damping force during the third compression movement distance.2. The system of claim 1 , wherein the inner piston assembly comprises an element for engaging the primary piston assembly.3. The system of claim 2 , wherein said element comprises at least one aperture that ...

ANIMAL PROTEIN-FREE PHARMACEUTICAL COMPOSITIONS

Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients. 1. A method to stabilize a Clostridial neurotoxin , comprising:providing an aqueous solution comprising a Clostridial neurotoxin and a non-mammalian protein excipient; andcompounding the solution with one or more additional non-protein excipients to provide a formulation comprising the neurotoxin in stable form.2. The method of claim 1 , wherein compounding comprises adding the one or more additional non-protein excipients to water to form a solution and adding the aqueous solution thereto.3. A pharmaceutical composition comprising:(a) a botulinum toxin, and;(b) a surfactant.4. The pharmaceutical composition of claim 3 , wherein the botulinum toxin is a biologically active botulinum toxin.5. The pharmaceutical composition of claim 3 , wherein the botulinum toxin is selected from the group consisting of the botulinum toxins types A claim 3 , B claim 3 , C claim 3 , D claim 3 , E claim 3 , F and G.6. The pharmaceutical composition of claim 3 , wherein the botulinum toxin is a botulinum toxin type A.7. The pharmaceutical composition of claim 3 , wherein a function of the polyvinylpyrrolidone is to stabilize the botulinum toxin. A pharmaceutical composition is a formulation comprises at least one active ingredient and at least one inert ingredient, called an excipient, used as a diluent or vehicle for the active ingredient. An excipient is useful in one or more of the following as a stabilizing agent, a bulking agent, a cryo-protectant, a lyo-protectant, a preservative, and a buffer. A pharmaceutical composition can be processed into a solid form, such as, e.g., a lyophilized (freeze dried), or vacuum dried powder which can be reconstituted with a suitable fluid, such as saline or water, prior to administration to a patient. Alternately, a pharmaceutical composition can be formulated as an aqueous solution or ...

SUSTAINED RELEASE POLOXAMER CONTAINING PHARMACEUTICAL COMPOSITIONS

A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system from which the biologically active botulinum toxin is released over a multi-day period thereby localizing the drug as a depot and controlling release to enhance the therapeutic effect per dose. 1. A thermoreversible , thermoplastic , pharmaceutical composition consisting of: (a) a biologically active botulinum toxin , and; (b) a thermoplastic poloxamer , wherein the thermoreversible , thermoplastic , pharmaceutical composition is transitionable from a low viscosity liquid solution for easy passage through a needle prior to administration by injection to a patient to a gel after administration.2. The pharmaceutical composition of claim 1 , wherein the poloxamer is a poloxamer 407.3. The pharmaceutical composition of claim 1 , wherein the biologically active botulinum toxin is a botulinum toxin type A.4. The pharmaceutical composition of claim 1 , wherein the biologically active botulinum toxin is a botulinum toxin type B.5. The pharmaceutical composition of claim 1 , wherein the biologically active botulinum toxin is a neurotoxic component of a botulinum toxin.6. A method for treating a medical or cosmetic condition claim 1 , the method comprising the step of administering to a patient a thermoreversible claim 1 , thermoplastic claim 1 , pharmaceutical composition consisting of a biologically active botulinum toxin and a thermoplastic poloxamer claim 1 ,wherein the thermoreversible, thermoplastic, pharmaceutical composition is transitionable from a low viscosity liquid solution for easy passage through a needle prior to administration by injection to a patient to a gel after ...

LOCKBOLT COLLAR FEEDER FOR SWAGING TOOL

A lockbolt collar feeder employing a resilient holder coupled to a linear actuator via a positioning arm, where the resilient holder can receive a lockbolt collar from a collar dispensing mechanism while disposed in a first position, and then when the linear actuator is extended the positioning arm extends and rotates the resilient holder to a second position in which the resilient holder can facilitate positioning the lockbolt collar onto a lockbolt for subsequent swaging. The linear actuator of the lockbolt collar feeder is configured to be coupled to a swaging tool, and thereby facilitates a method of positioning a lockbolt collar onto a lockbolt using the swaging tool. 1. A lockbolt collar feeder for a swaging tool , comprising:a linear actuator configured to be coupled to the swaging tool;a positioning arm coupled to an end of the linear actuator and configured to rotate about an axis of the linear actuator as the linear actuator extends from a retracted position to an extended position; wherein when the linear actuator is retracted the positioning arm rotates to a first collar-loading position in which the resilient holder is adjacent to and aligned with a collar dispensing mechanism to receive the collar from the collar dispensing mechanism, and', 'when the linear actuator is extended the positioning arm is biased to rotate about the axis of the linear actuator to a second collar-installing position in which the resilient holder is distal to and in approximate alignment with the end of the swaging tool to facilitate positioning the collar onto the lockbolt; and retraction of the linear actuator after positioning the collar onto the lockbolt causes the resilient holder to release from the collar positioned on the lockbolt, and causes the positioning arm to return to the first collar-loading position, thereby moving the resilient holder away from the end of the swaging tool for preventing interference with operation of the swaging tool., 'a resilient holder ...

Spring Washer Compression Limiter

A limiting spring washer includes a main body portion and a side portion, which may be a frustoconical, extending from the main body portion. The main body portion defines a washer aperture therethrough. The main body portion is thicker than the side portion. A bolt assembly includes a part defining a part aperture therethrough. A limiter is disposed within the part aperture. A bolt is configured to attach the part to an item. In the bolt assembly, the limiting spring washer is disposed in contact with the limiter, the bolt, and the part. The bolt is configured to apply a total load, a first portion of the total load being absorbed by the part, and a second portion of the total load being absorbed by the limiter. 1. A limiting spring washer comprising:a main body portion defining an aperture therethrough, the main body portion having a main body thickness;a side portion extending from the main body portion, the side portion having a leg thickness, the main body thickness being greater than the leg thickness.2. The limiting spring washer of claim 1 , the main body portion having a flat base surface disposed in a base plane claim 1 , the side portion being frustoconical and extending at an angle with respect to the base portion in an uncompressed state claim 1 , the angle being in the range of 110 degrees to 178 degrees.3. The limiting spring washer of claim 2 , the main body portion having an external surface opposite the base surface and disposed in an outer plane that is parallel to the base plane claim 2 , the main body thickness extending between the base surface and the external surface.4. The limiting spring washer of claim 3 , the external surface and the outer plane being offset from the side portion.5. The limiting spring washer of claim 4 , the side portion defining a circular outer edge that is offset from the base plane and the outer plane.6. The limiting spring washer of claim 5 , the main body portion defining a solid annulus having the main body ...

HANDSHOWER SLIDE MECHANISM

A handshower slide includes a bar with a passageway, a slide mechanism positioned along a length of the bar, and a showerhead holder movable with the slide mechanism along the length of the bar. The slide mechanism includes a handle and a cam, and the cam is positioned within the passageway and is rotatable between a first orientation and a second orientation relative to the bar. The slide mechanism is not movable along the length of the bar while the cam is in the first orientation and is movable along the length of the bar while the cam is in the second orientation. An orientation of the cam is correlated to a position of the handle, and a spring is coupled to the handle and the cam, so that the spring biases the cam toward the first orientation and away from the second orientation. 1. An adjustable showerhead slide comprising:a bar with a passageway;a slide mechanism positioned along a length of the bar;a showerhead holder movable with the slide mechanism along the length of the bar,wherein the slide mechanism comprises a handle and a cam,wherein the cam is positioned within the passageway and is rotatable between a first orientation and a second orientation relative to the bar,wherein the slide mechanism is not movable along the length of the bar while the cam is in the first orientation and is movable along the length of the bar while the cam is in the second orientation,wherein an orientation of the cam is correlated to a position of the handle; anda spring coupled to the handle and the cam, wherein the spring biases the cam toward the first orientation and away from the second orientation.2. The adjustable showerhead slide of claim 1 , wherein the cam moves from the first orientation to the second orientation when the handle moves the cam counter to a force of the spring.3. The adjustable showerhead slide of claim 1 , wherein the cam is frictionally engaged with the bar in the first orientation and not frictionally engaged with the bar in the second ...

A RACK ASSEMBLY STRUCTURE

Embodiments of the present disclosure provide techniques and configurations for a rack assembly. In one embodiment, a tray to be disposed in a rack assembly may comprise a plurality of sleds with individual sleds including one or more compute nodes; and a networking element coupled with a sled of the plurality of sleds and configured to communicatively connect the sled to one or more other components of the rack assembly via an optical communication system. The optical communication system may include an external optical cable configured to communicatively connect the networking element with the rack assembly. Other embodiments may be described and/or claimed.

HANGER WITH SECUREMENT ELEMENT

A garment hanger includes a hook and an arm. The hook is configured to receive a support rod, and the arm is coupled to the hook and extends outwardly to a free arm end. The arm includes a first substantially planar panel and a top panel extending rearwardly from a top edge of the first substantially planar panel. The arm further includes an indentation and a finger. The indentation is defined adjacent the first substantially planar panel to be at least partially open in a direction facing away from the first substantially planar panel. The indentation defines an outermost edge nearest the free arm end and an innermost end nearest the hook. The finger extends from one of the outermost edge and the innermost edge of the indentation toward the other and is configured to hold a portion of a garment within the indentation. 1. A garment hanger comprising:a hook configured to selectively receive a support rod; a first substantially planar panel facing toward one of a front and a rear of the garment hanger,', 'a top panel extending rearwardly from a top edge of the first substantially planar panel,', 'an indentation defined adjacent the first substantially planar panel and below the top panel to be at least partially open in a direction facing away from the first substantially planar panel, the indentation defining an outermost edge nearest the free arm end and an innermost end nearest the hook, and', 'a finger extending from one of the outermost edge and the innermost edge of the indentation toward the other one of the outermost edge and the innermost edge of the indentation and being configured to hold a portion of a garment within the indentation, wherein the finger is formed adjacent the indentation opposite the first substantially planar panel., 'an arm coupled to the hook and extending outwardly to a free arm end, wherein the arm includes2. The garment hanger of claim 1 , wherein the finger defines an exterior-facing surface opposite the indentation claim 1 , and the ...

METHODS AND DEVICES FOR TREATING POLYCYSTIC KIDNEY DISEASE AND ITS SYMPTOMS

Apparatus, systems, and methods for treating PKD by providing access to a patient's renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances to ablate a thin layer of tissue lining at least a portion of the renal pelvis to disrupt renal nerves within the tissue lining of the renal pelvis. 1. A method for treating PKD , the method comprising:selecting a patient diagnosed with PKD;positioning a distal end of a catheter into an interior of the patient's kidney; anddelivering an amount of energy through a wall of the kidney to denervate adjacent nerves to treat the PKD.2. A method as in claim 1 , wherein the energy is RF energy delivered via one or more flexible wires on the distal end of the catheter.3. A method as in claim 2 , wherein the one or more flexible wires are manipulable between a first position wherein the one or more flexible wires are within the lumen claim 2 , and a second position wherein the one or more flexible wires are extended out of the lumen through the opening.4. A method as in claim 3 , wherein the one or more flexible wires are configured to deliver energy to the renal nerve when the one or more flexible wires are in the second position.5. A method as in claim 2 , wherein the catheter is inserted to the first position within the conduit claim 2 , the first distal end is positioned adjacent to a renal nerve claim 2 , the one or more flexible wires are through the lumen or the catheter is retracted so that the one or more flexible wires extend out of the lumen through the opening adjacent the renal nerve. This application claims the benefit of provisional patent application 62/505,686 (Attorney Docket No. 42532-710.101), ...

SUSTAINED RELEASE POLOXAMER CONTAINING PHARMACEUTICAL COMPOSITIONS

A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system from which the biologically active botulinum toxin is released over a multi-day period thereby localizing the drug as a depot and controlling release to enhance the therapeutic effect per dose. 124-. (canceled)25. A method for treating a medical or cosmetic condition , the method comprising the step of administering to a patient a thermoreversible , thermoplastic , pharmaceutical composition consisting of a biologically active botulinum toxin type A present as a complex with human serum albumin and a thermoplastic poloxamer , wherein the thermoreversible , thermoplastic , pharmaceutical composition is transitionable from a low viscosity liquid solution for easy passage through a needle prior to administration by injection to a patient to a gel after administration26. The method of claim 25 , wherein the thermoplastic poloxamer is a poloxamer 407.27. The method of claim 25 , wherein treating the medical or cosmetic condition comprises treating at least one of glabellar lines claim 25 , nasolabial lines claim 25 , crows feet claim 25 , marionette lines and horizontal lines of the forehead.28. The method of claim 25 , wherein treating the medical or cosmetic condition comprises treating at least one of overactive bladder claim 25 , hyperhidrosis claim 25 , benign prostatic hyperplasia and a dystonia.29. The method of claim 25 , wherein the botulinum toxin type A is present in an amount from about 5 units to about 2750 units.30. The method of claim 25 , further comprising the step of placing a cooling or heating element over an area of administration before or after the administration ...

WATERCRAFT HAVING RETRACTABLE DRIVE MECHANISM

Examples are disclosed that relate to watercraft with retractable drive mechanisms. One example provides a watercraft including a hull having a receiving compartment, and also having a deck. The watercraft also includes a drive unit extending through the deck and the hull of the watercraft and being configured to receive rotational input. The drive unit includes a driveshaft and propeller moveable between an extended position in which the propeller is positioned underneath the hull and a retracted position in which the propeller is positioned at least partially within the receiving compartment. 1. A watercraft , comprising:a hull comprising a receiving compartment;a deck positioned above the hull; an input coupling configured to receive rotational input,', 'a flexible drive shaft connecting the input coupling to a propeller, the flexible drive shaft and propeller moveable between an extended position in which the propeller is positioned underneath a bottom side of the hull and a retracted position in which the propeller is positioned at least partially within the receiving compartment; and, 'a drive unit extending through the deck and the hull of the watercraft, the drive unit comprisinga drive retraction control linked to the drive unit to move the flexible drive shaft and propeller between the extended and retracted positions.2. The watercraft of claim 1 , further comprising a detachable pedal apparatus positioned above the deck of the watercraft claim 1 , where the input coupling is configured to receive rotational input from the detachable pedal apparatus in a user powered configuration.3. The watercraft of claim 2 , further comprising a detachable motor claim 2 , where the input coupling is configured to receive rotational input from the detachable motor in a motor-powered configuration.4. The watercraft of claim 3 , where the detachable motor is an electric motor coupled to a battery.5. The watercraft of claim 1 , where the input coupling is a quick disconnect ...

Apparatus and Process for Liquefying Gases

A liquefier device which may be a retrofit to an air separation plant or utilized as part of a new design. The flow needed for the liquefier comes from an air separation plant running in a maxim oxygen state, in a stable mode. The three gas flows are low pressure oxygen, low pressure nitrogen, and higher pressure nitrogen. All of the flows are found on the side of the main heat exchanger with a temperature of about 37 degrees Fahrenheit. All of the gasses put into the liquefier come out as a subcooled liquid, for storage or return to the air separation plant. This new liquefier does not include a front end electrical compressor, and will take a self produced liquid nitrogen, pump it up to a runnable 420 psig pressure, and with the use of turbines, condensers, flash pots, and multi pass heat exchangers. The liquefier will make liquid from a planned amount of any pure gas oxygen or nitrogen an air separation plant can produce. 1. A liquefier device configured for use with an air separation plant comprising;a heat exchanger system provided in an insulated housing containing an oxygen cooler, a preheater, a boiler, a condenser, an added cooler heat exchanger, a turbine exhaust phase separator, an oxygen production flash pot, a nitrogen production flash pot, a nitrogen pump flash pot, a plurality of level control valves for controlling the liquid height of a nitrogen bath in the flash pots, and a system of inlet and outlet lines connecting therebetween,an oxygen gas stream, a low pressure nitrogen gas stream, and a high pressure gas nitrogen stream from the air separation plant to the heat exchanger system,a turbine assembly operably connected to the heat exchanger system including a plurality of turbine expanders connected in parallel, and a plurality of turbine boosters connected in series, each turbine expander and turbine booster having an associated inlet flow meter, each turbine expander having variable guide vanes, and each turbine booster having an associated ...

METHOD TO MANUFACTURE A STABLE PROTEIN

A Clostridial toxin pharmaceutical composition comprising a Clostridial toxin, such as a botulinum toxin, wherein the Clostridial toxin present in the pharmaceutical composition is stabilized by a non-protein excipient such as a polyvinylpyrrolidone, a disaccharide, a trisaccharide, a polysaccharide, an alcohol, a metal, an amino acid, a surfactant and/or a polyethylene glycol. 1. A method to stabilize a toxin that cleaves SNAP-25 , comprising:compounding to form a liquid pharmaceutical composition a Clostridial neurotoxin and two or more non-protein excipients, wherein the non-protein excipients are non-immunogenic response injected into a human and effective to stabilize the Clostridial neurotoxin for activity to cleave SNAP-25.2. The method of claim 1 , wherein compounding comprises adding the non-protein stabilizer to water to form a solution and adding the Clostridial neurotoxin to the solution to form a toxin formulation.3. The method of claim 2 , wherein the toxin formulation is an aqueous solution. This application is a continuation of U.S. application Ser. No. 14/139,519, filed Dec. 23, 2013, pending, which is a continuation of U.S. application Ser. No. 13/369,632, filed Feb. 9, 2012, now U.S. Pat. No. 8,642,047, which is a continuation of U.S. application Ser. No. 11/524,683, filed Sep. 21, 2006, now U.S. Pat. No. 8,137,677, which claims priority to U.S. Provisional Application No. 60/725,126, filed Oct. 6, 2005, the entire content of each application is incorporated herein by reference.The present invention relates to Clostridial toxin pharmaceutical compositions. In particular, the present invention relates to Clostridial toxin pharmaceutical compositions with a non-protein excipient which functions to stabilize the Clostridial toxin (such as a botulinum toxin) present in the pharmaceutical composition.A pharmaceutical composition is a formulation which contains at least one active ingredient (such as a Clostridial toxin) as well as, for example, one or ...

EVENT-RELATED MEDIA MANAGEMENT SYSTEM

An event-related media management system contextualizes media content. The event-related media management system associates media content with contextual event-related data to associate the media content with the events and information about the events. The contextual event-related data can then be used to provide access to the media content, such as through relevant search results or by presenting the media content in organized displays for contextual browsing and navigation. In some embodiments the event-related media management system generates contextualized media content for contextual search, discovery, and advertising. 1. A method of automatically generating tags for media content , the method comprising:storing event-related data associated with at least one event including a particular event in at least one computer readable storage device, the event-related data including discrete action data identifying discrete actions that occur during the particular event including a particular discrete action;identifying contextual information associated with a particular media content item using the at least one computing device;determining that the particular media content item relates to the particular event of the at least one event based at least in part on the contextual information, using the at least one computing device;automatically generating a tag identifying the particular event for the particular media content item using the at least one computing device;comparing the contextual information to the discrete action data for the particular event to identify a relationship between the particular media content item and the particular discrete action; andautomatically generating a tag identifying the particular discrete action of the particular event as a result of the identified relationship between the particular media content item and the particular discrete action.2. The method of claim 1 , further comprising generating and storing a text-based message ...

RENAL NERVE DENERVATION VIA THE RENAL PELVIS

Apparatus, systems, and methods provide access to the renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances. 1. (canceled)2. A method for inhibiting the function of renal nerves in a kidney of a patient suffering from hypertension , said method comprising:percutaneously advancing an effector comprising an array of electrodes into an interior of the kidney or an upper region of an adjacent ureter;expanding the array of electrodes within the kidney or the upper region of the adjacent ureter to engage an interior wall of a renal pelvis; anddelivering radiofrequency energy from the array of electrodes through the interior wall of the renal pelvis to ablate afferent sensory nerves within the wall of the renal pelvis wherein blood pressure of the patient is reduced.3. A method as in claim 2 , wherein the radiofrequency energy is delivered for a time in a range from 1 to 2 minutes.4. A method as in claim 2 , wherein a temperature of a tissue bed in the wall of the renal pelvis surrounding the afferent sensory nerves is raised to a temperature in a range from 45° C. to 60° C.5. A method as in claim 4 , further comprising irrigating the expanded array of electrodes to maintain a temperature of papillae claim 4 , parenchyma claim 4 , and pyramids in the kidney below 45° C.6. A method as in claim 2 , wherein percutaneously advancing the effector comprises forming a percutaneous penetration through the patient's abdominal wall to the kidney.7. A method as in claim 6 , wherein advancing the effector through the patient's abdominal wall to the kidney is performed laparoscopically.8. A method as in claim 7 , further comprising insufflating the patient's ...

Apparatus for Layup Placement

Method and apparatus for layup placement on a layup structure is provided. The method includes iteratively loading a layup for the layup structure on a support frame of a saddle module; aligning the saddle module with a pre-selected registration position corresponding to a predetermined application path on the layup structure; and impressing the layup into forced contact with the layup structure along the predetermined application path using a predetermined application force. The apparatus includes a plurality of saddle modules configured to operate in unison, wherein the plurality of saddle modules is configured to receive a pre-selected composite material layup.

SELF-TAPPING COMPRESSION LIMITER

A self-tapping compression limiter for a structure of an automotive vehicle. The limiter includes a body having a first end extending to a second end. The body has a bore formed through the first and second ends defining a longitudinal axis. The body has an outer wall having a shoulder radially extending from the outer wall and formed adjacent one of the first and second ends to reduce tolerance to the structure. The outer wall has a threaded portion formed about the longitudinal axis. The threaded portion is matingly cooperable with the structure to provide a positive lock interface between the limiter and the structure. 1. A self-tapping compression limiter for a structure of an automotive vehicle , the limiter comprising:a body having a first end extending to a second end, the body having a bore formed through the first and second ends defining a longitudinal axis, the body having an outer wall having a shoulder radially extending from the outer wall to a contact portion configured to contact the structure, the shoulder being formed adjacent one of the first and second ends to reduce tolerance to the structure, the outer wall having a threaded portion formed about the longitudinal axis, the threaded portion being matingly cooperable with the structure to provide a positive lock interface between the limiter and the structure.2. The limiter of wherein the inner wall comprises a shaped drive formed at one of the first and second ends allowing torque to be applied to the limiter.3. The limiter of wherein the shaped drive is a female hex drive.4. The limiter of wherein the outer wall comprises a shaped drive formed at one of the first and second ends allowing torque to be applied to the limiter.5. The limiter of wherein the shaped drive is a male hex drive.6. The limiter of wherein the body comprises steel claim 1 , aluminum claim 1 , brass claim 1 , bronze claim 1 , copper claim 1 , or alloys thereof.7. An automotive assembly with self-tapping compression claim 1 , ...

RENAL NERVE DENERVATION VIA THE RENAL PELVIS

Apparatus, systems, and methods provide access to the renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances. 1. A system for inhibiting the function of renal nerves in a kidney of a patient suffering from hypertension , said system comprising:an effector comprising an array of electrodes configured to be advanced on a member into an interior of the kidney or an upper region of an adjacent ureter;wherein the array of electrodes is configured to be expanded within the kidney or the upper region of the adjacent ureter to engage an interior wall of a renal pelvis and to deliver radiofrequency energy from the array of electrodes through the interior wall of the renal pelvis to ablate nerves within the wall of the renal pelvis wherein blood pressure of the patient is reduced; anda continuous irrigation means through the member to cool the array of electrodes to reduce heat damage to tissue in contact with the electrodes.2. A system as in claim 1 , wherein the member comprises a urinary catheter configured be advanced through the patient's urethra claim 1 , the patient's bladder claim 1 , and the patient's kidney or upper region of the adjacent ureter.3. A system as in claim 1 , wherein the member comprises a percutaneous access tool configured to be advanced into the patient's retroperitoneal space and into a hilum of the patient's kidney.4. A system as in claim 3 , wherein the percutaneous access tool is further configured to be advanced into the patient's renal pelvis5. A system as in claim 1 , further comprising a controller.6. A system as in claim 5 , wherein the controller is configured to deliver radiofrequency energy for a time in a range ...

REGION PROPOSAL NETWORKS FOR AUTOMATED BOUNDING BOX DETECTION AND TEXT SEGMENTATION

A processor may generate a plurality of intermediate feature layers of an image using convolutional neural network (CNN) processing. For each intermediate feature layer, the processor may generate a plurality of text proposals using a region proposal network (RPN). Each text proposal may comprise a portion of the intermediate feature layer that is predicted to contain text. The processor may perform OCR processing on image data within a plurality of regions of the image to generate a text result for each region. Each region may comprise at least one of the text proposals. The processor may assemble the text results into a text string comprising the text results ordered according to a spatial order in which the plurality of regions appear within the image. 1. An optical character recognition (OCR) processing system , the system comprising:a memory configured to store an image and a plurality of instructions; and generating a plurality of intermediate feature layers of an image using convolutional neural network (CNN) processing, the generating comprising forming a convolutional layer and mapping a plurality of portions of the convolutional layer onto respective intermediate features using a network;', 'for each intermediate feature layer, generating a plurality of text proposals using a region proposal network (RPN), each text proposal comprising a portion of the intermediate feature layer that is predicted to contain text, the generating comprising obtaining a predicted bounding box from a box-regression layer and obtaining a probability of the predicted bounding box including text from a box-classification layer;', 'performing OCR processing on image data within a plurality of regions of the image, each region being formed from at least one of the text proposals, to generate a text result for each region; and', 'assembling the text results into a text string comprising the text results ordered according to a spatial order in which the plurality of regions appear ...

Valve

A valve including indicating means for indicating overtravel of an operating member beyond its normally closed position for warning that replacement of a seal is necessary. A diaphragm valve has a diaphragm of a material which withstands repeated flexing and is clamped in a unique manner.

Valve

A valve including indicating means for indicating overtravel of an operating member beyond its normally closed position for warning that replacement of a seal is necessary. A diaphragm valve has a diaphragm of a material which withstands repeated flexing and is clamped in a unique manner.

External dried-reagent control for analytical test devices

A control device serving as a source of control reagent for a solid-phase analytical test device is disclosed. The analytical test device analyzes a biological sample for the presence of an analyte such as an enzyme or other chemical species or a particular pH range, and registers the presence or absence of the analyte as a detectable change in an indicator. The control device contains a control reagent that produces the same indicator change and that can be transferred to the analytical test device by a sample implement such as a wet swab. The control reagent is present on the control device as a dry lamina or combination of laminae. A positive control reagent on a control device in accordance with this invention mimics the action of the analyte once it is transferred to the analytical test device, while a negative control reagent on the control device mimics the action of a sample that lacks the analyte.

Acoustic wave touch actuated system

A touch pad assembly includes a substrate and a plurality of acoustic wave switches positioned with respect to the substrate. Each of the plurality of acoustic wave switches includes a touch surface connected to an acoustic wave cavity and a transducer secured to the acoustic wave cavity. The plurality of acoustic wave switches are positioned to provide detection of sliding motion direction and rate between the plurality of acoustic wave switches.

Systems and methods for disinfecting contact lenses

A system for disinfecting a contact lens includes a first container section holding a first liquid medium containing hydrogen peroxide. A second container section is provided and holds a second liquid medium containing a hydrogen peroxide destroying component. The first and second container sections are configured to substantially simultaneously provide the first liquid medium and the second liquid medium to form a combined liquid medium containing an amount of hydrogen peroxide from the first liquid medium effective to disinfect a contact lens contacted with the combined liquid medium and an amount of hydrogen peroxide destroying component from the second liquid medium effective to destroy at least a major amount of the hydrogen peroxide in the combined liquid medium.

Clostridial toxin pharmaceutical compositions

Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin ac-tive ingredient and at least two excipients.

High-speed video graphics system and method for generating solid polygons on a raster display

A real-time video graphics system for generating solid polygons on a raster display screen from X-Y vertex coordinates of the polygons. Solid objects are defined in a host processor system as three-dimensional polygons. The host processor calculates the X-Y vertex coordinates for each polygon and deposits them, along with a corresponding instruction and pixel video data, in a shared RAM. The video graphics system obtains the instruction and data from the shared RAM and calculates from the X-Y vertex coordinates the X coordinates of the left and right edges of each solid polygon for each horizontal line of the display. The system writes pixel data for a horizontal stripe of 32 pixels into a frame buffer in one frame buffer memory write cycle of approximately 320 nanoseconds. Pixel data is periodically read out of the frame buffer, one complete stripe at a time, and shifted out serially to refresh the display screen.

Pressure sensor with a radially tensioned metal diaphragm

A pressure sensor having a radially tensioned diaphragm for measuring fluid pressure. The pressure sensor includes a first generally concave metal body member and a second generally concave metal body member, and a radially tensioned flexible metal diaphragm disposed therebetween that is tensioned by heating the sensor. The first and second body members are formed from a material having a coefficient of thermal expansion in the range of approximately 0.0000056 inch/inch/°F to 0.0000064 inch/inch/°F. The diaphragm is formed from a precipitation hardening metal material having a coefficient of thermal expansion of approximately 0.0000060 inch/inch/°F. The first body member and the second body member are formed from a ferromagnetic metal material such that the first and second body members shield the diaphragm from magnetic fields which may otherwise cause movement of the diaphragm.

Methods of treating cancer using glucagon-like hormone retargeted endopeptidases

The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.

Valve for use in a suction line

Abstract of the Disclosure The valve comprises a housing connected to the outlet of a teat cup assembly. The housing includes a nipple formed in the bottom portion thereof for connection to a milk suction line. A ball member is mounted inside the valve housing and adapted to seat at the opening from the housing into the nipple when the interior of the housing is exposed to atmospheric pressure. The valve further includes a plunger slidably mounted in the wall of the valve housing, and the plunger is adapted to slide inwardly into the valve housing when the pressure in the housing falls below atmospheric pressure. The inward movement of the plunger is adapted to dislodge the ball member from its seated position at the nipple opening. The plunger member has an elastomeric washer mounted thereon which seals against the housing when the plunger slides inwardly. The washer has a locking ear thereon which engages a projection on the housing to lock the plunger in its retracted position during cleaning.

Wireless synchronous time system with solar powered transceiver

A primary device for a synchronous event system. In one construction, the primary device includes a solar panel operable to convert light into electricity; a receiver operable to receive a global positioning system time signal; a processor coupled to the receiver and operable to process the global positioning system time signal to produce a processed time component; a internal clock coupled to the processor and operable to store the processed time component and to increment relative to the processed time component thereafter to produce an internal time; and a transmitter coupled to the processor and operable to transmit the internal time to a secondary device for wireless reception by the secondary device and synchronization of the secondary device relative to the primary device.

Botulinum toxin compositions

A high potency botulinum toxin pharmaceutical composition comprising two excipients (such as albumin and sodium chloride) in a weight to weight ratio of between about 1 and about 100.

Implantable medical device battery

A battery comprises a tubular housing. An external surface of the tubular housing comprises a biocompatible material. The battery further comprises a battery header secured to an open end of the tubular housing, and the tubular housing and the battery header combine to form a substantially sealed enclosure. The battery also comprises one or more voltaic cells within the substantially sealed enclosure, and a feedthrough electrically connected to the voltaic cells and extending through the battery header to form a battery terminal. The battery header includes a radial groove opposite the tubular housing, and the radial groove is configured to receive a mating snap-fit electronic component subassembly of an implantable medical device.

Non-protein stabilized clostridial toxin pharmaceutical compositions

A Clostridial toxin pharmaceutical composition comprising a Clostridial toxin, such as a botulinum toxin, wherein the Clostridial toxin present in the pharmaceutical composition is stabilized by a non-protein excipient such as a polyvinylpyrrolidone, a disaccharides, a trisaccharide, a polysaccharide, an alcohol, a metal, an amino acid, a surfactant and/or a polyethylene glycol.

Pre-trained contextual embedding models for named entity recognition and confidence prediction

At least one processor may obtain a document comprising text tokens. The at least one processor may determine, based on a pre-trained language model, word embeddings corresponding to the text tokens. The at least one processor may determine, based on the word embeddings, named entities corresponding to the text tokens; and one or more accuracy predictions corresponding to the named entities. The at least one processor may compare the one or more accuracy predictions with at least one threshold. The at least one processor may associate, based on the comparing, the named entities with one or more confidence levels. The at last one processor may deliver the named entities and the one or more confidence levels.

Process for producing low or non fat ice cream

Low or non-fat ice cream contains less than about 5% by weight fat and comprises (by weight except where otherwise stated) from about 5 to about 15% milk solids non-fat, from about 5 to about 20% sweeteners. from about 0.1 to about 0.5% stabilizers and, at a temperature in the range of from about -12 to about -10°C, from about 45 to about 60% frozen water in the form of ice crystals, at least about 40% (by number) of said ice crystals having a diameter less than about 45 microns, and from about 10 to about 20% unfrozen water.

Traceable record generation system and method using wireless networks

Composition and method for hydrocarbon and lipid degradation and dispersal

The present invention is directed toward a bioremediation product, its method of manufacture and its method of use. A blend of microorganisms (e.g. Bacillus, Pseudomonas, Paenibacillus and Aspergillus), cleansers and surfactants including cocamidopropyl betaine, tall oil fatty acid, monoethanolamine, octylphenol oxylates, ficoll, sucrose, fructose, glycine and glycerol is disclosed which is non-toxic and solvent free and which has the ability to accelerate the breaking down process of oils, materials such as benzene, toluene and xylene (BTEX), petroleum hydrocarbon fraction F1-F4 (as defined by CCME2000), polyeyelic aromatic hydrocarbons (PAH), paraffin/waxes, volatile organics, molds and the like: which simultaneously providing a biological component which is effective to reduce the total petroleum hydrocarbon levels to zero at an accelerated rate. The product is useful for bioremediation and as an oil dispersant composition useful in treating oil spills and cleanup of the shoreline, animals, plants and equipment.

Light beam attenuation

Variable attenuation of a light beam is achieved by mounting a rotatable multilayer dielectric attenuator in the beam. A first portion of the beam is transmitted through the attenuator and a second portion is reflected. Rotation of the attenuator about an axis transverse to the beam varies the ratio between these portions. The main application of this attenutator is to control an output characteristic, e.g. output power, of a laser, and may include a feedback loop to maintain this characteristic constant.

distinct fluid level sensor and mounting

SENSOR DE NìVEL DE FLUIDO DISTINTO E MONTAGEM. Um sensor de nível para determinar a presença ou ausência de um líquido em contato com o sensor, inclui uma sonda alongada, um transdutor conectado de modo operável na sonda e configurado para produzir ondas de compressão na sonda, e conjunto de circuitos para detectar a energia acústica emitida no líquido, quando o líquido está em contato com a sonda. Uma montagem para reter de modo liberável um sensor de nível, inclui uma base tem uma região de recepção formada em parte por uma pluralidade de dedos de fixação flexíveis. Os dedos têm projeções de travamento se estendendo a partir dos mesmos. Um contato é montado na base e estendendo na região de recepção. Um cartucho suporta o sensor de nível e é recebido na região de recepção. O cartucho inclui um recesso circunferencial para receber os dedos de fixação. Quando o sensor de nível é posicionado no cartucho e o cartucho é inserido na base, o sensor de nível é conectado de modo operável no contato e o cartucho é preso de modo resiliente na base. DISTINCT FLUID LEVEL SENSOR AND ASSEMBLY. A level sensor for determining the presence or absence of a liquid in contact with the sensor includes an elongated probe, a transducer operably connected to the probe and configured to produce probe compression waves, and circuitry to detect the energy. acoustic emission in the liquid when the liquid is in contact with the probe. An assembly for releasably retaining a level sensor includes a base having a receiving region formed in part by a plurality of flexible attachment fingers. The fingers have locking projections extending from them. A contact is mounted on the base and extending into the receiving region. A cartridge supports the level sensor and is received in the receiving region. The cartridge includes a circumferential recess for receiving the fixing fingers. When the level sensor is positioned in the cartridge and the cartridge is inserted into the base, the level sensor is ...

Homogeneous long-life oxidation catalysts

Patente de Invenção: "CATALISADORES DE OXIDAçãO HOMOGêNEOS DE LONGA VIDA". Apresenta-se um complexo de quelato robusto com a fórmula (I), em que M é um metal, de preferência um metal de transição; Z é um átomo doador aniónico, pelo menos três dos quais são nitrogênio, e o outro é, de preferência, nitrogênio ou oxigênio; L, é um ligante instável; Ch~ 1~, Ch~ 2~ e Ch~ 3~ são grupos quelatos resistentes à oxidação, que são iguais ou diferentes e que formam anéis de 5 ou 6 elementos com o metal, e Ch~ 4~ é um grupo quelato com a estrutura (a), em que R~ 1~ e R~ 2~ são iguais ou diferentes, e são, de preferência, selecionados no grupo que consiste em hidrogênio, halogênio, metila e CF~ 3~, ou, quando ligados, um substituinte ciclo de anel de 5 ou 6 elementos. O complexo fornece um catalisador ou ativador de catalisador de oxidação estável e de longa vida.

Graphical printing system and method using text triggers

A set of new printing functions are implemented as defining commands to make it possible to add graphic effects to a printout of a POS printer. These functions are based on a method of designating usually cyclically re-occurring byte strings, usually text in receipts, to act as triggers to launch the graphics function. These functions include optionally eliminating some text, adding graphic surrounds about designated lines, changing the color of designated lines, and inserting logos between or merging logos with text. Such usage need not make any changes to existing store lane checkout applications. Configuring new custom commands in POS printers permits defining byte string triggers occurring in receipt text that are used to trigger adding graphics to the receipt output.

Manufacturing system for aircraft structures and other large structures

A production system for manufacturing a workpiece comprises an index system including a plurality of index devices removably mounted on the workpiece at known longitudinally spaced locations therealong, and a longitudinally extending index member releasably engaged with at least two of the index devices such that a position and orientation of the index are fixed relative to the workpiece by the index devices, the index member having position-indicating features distributed therealong. The production system further comprises a machine module mounted for longitudinal movement along the index member and operable to perform an operation, the machine module being operable to detect the position-indicating features on the index member and thereby determine a position of the machine module relative to the workpiece.

Earphone

Manufacturing system for aircraft structures and other large structures

A production system for manufacturing a workpiece comprises an index system including a plurality of index devices removably mounted on the workpiece at known longitudinally spaced locations therealong, and a longitudinally extending index member releasably engaged with at least two of the index devices such that a position and orientation of the index are fixed relative to the workpiece by the index devices, the index member having position-indicating features distributed therealong. The production system further comprises a machine module mounted for longitudinal movement along the index member and operable to perform an operation, the machine module being operable to detect the position-indicating features on the index member and thereby determine a position of the machine module relative to the workpiece.

Non-protein stabilized clostridial toxin pharmaceutical compositions